10541328

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626GMS

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS 3	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS 4	MAR 31	CA/CAplus and CASREACT patent number format for U.S. applications updated
NEWS 5	MAR 31	LPCI now available as a replacement to LDPCI
NEWS 6	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 7	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS 8	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS 9	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS 10	APR 28	IMSRESEARCH reloaded with enhancements
NEWS 11	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS 12	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS 13	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS 14	JUN 06	KOREAPAT updated with 41,000 documents
NEWS 15	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS 16	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS 17	JUN 25	CA/CAplus and USPAT databases updated with IPC reclassification data
NEWS 18	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS 19	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS 20	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS 21	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS 22	JUL 28	CA/CAplus patent coverage enhanced
NEWS 23	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS 24	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 25	JUL 28	STN Viewer performance improved
NEWS 26	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced

```
 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:41:20 ON 04 AUG 2008

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files.  For example, the EXPAND
command can only be used to look at the index in a file which has an
index.  Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of
commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                 0.21       0.21

FILE 'REGISTRY' ENTERED AT 10:41:35 ON 04 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    2 AUG 2008  HIGHEST RN 1037774-47-2
DICTIONARY FILE UPDATES:   2 AUG 2008  HIGHEST RN 1037774-47-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
```

experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10541328.str





chain nodes :
7 9 10 12 15 16
ring nodes :
1 2 3 4 5 6
chain bonds :
3-12 4-7 6-16 9-10 9-12 10-15
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
1-2 1-6 2-3 3-4 3-12 4-5 4-7 5-6 6-16 9-10 9-12 10-15
isolated ring systems :
containing 1 :

G1:O,S,N

```
Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  9:CLASS  10:Atom  12:CLASS
 15:Atom  16:CLASS



L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR
```




```
G1 O,S,N


Structure attributes must be viewed using STN Express query preparation.


=> s l1
SAMPLE SEARCH INITIATED 10:41:50 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    27269 TO ITERATE

  7.3% PROCESSED     2000 ITERATIONS                                0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE   **COMPLETE**
                        BATCH    **COMPLETE**
PROJECTED ITERATIONS:       535500 TO   555260
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 10:41:57 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   553581 TO ITERATE

100.0% PROCESSED   553581 ITERATIONS                            69 ANSWERS
SEARCH TIME: 00.00.08

L3           69 SEA SSS FUL L1
```

```
=> FIL HCAPLUS
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                   178.36     178.57

FILE 'HCAPLUS' ENTERED AT 10:42:11 ON 04 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 4 Aug 2008  VOL 149 ISS 6
FILE LAST UPDATED: 3 Aug 2008  (20080803/ED)

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> s l3
L4            5 L3

=> s l4 and py<=2003
      24005635 PY<=2003
L5            1 L4 AND PY<=2003

=> d l4 ibib abs hitstr tot

L4   ANSWER 1 OF 5  HCAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2008:622524  HCAPLUS
TITLE:                    Characterization of EHT 1864, a novel small molecule
                          inhibitor of Rac family small GTPases
AUTHOR(S):                Onesto, Cercina; Shutes, Adam; Picard, Virginie;
                          Schweighoffer, Fabien; Der, Channing J.
CORPORATE SOURCE:         Lineberger Comprehensive Cancer Center, Department of
                          Pharmacology, University of North Carolina at Chapel
                          Hill, Chapel Hill, NC, USA
SOURCE:                   Methods in Enzymology (2008), 439(Small GTPAses in
                          Disease, Part B), 111-129
                          CODEN: MENZAU; ISSN: 0076-6879
PUBLISHER:                Elsevier
DOCUMENT TYPE:            Journal; General Review
LANGUAGE:                 English
AB   A review.  There is now considerable exptl. evidence that aberrant
```

activation of Rho family small GTPases promotes uncontrolled proliferation, invasion, and metastatic properties of human cancer cells. Therefore, there is considerable interest in the development of small mol. inhibitors of Rho GTPase function. However, to date, most efforts have focused on inhibitors that block Rho GTPase function indirectly, either by targeting enzymes involved in post-translational processing or downstream protein kinase effectors. We have reported the identification and characterization of the EHT 1864 small mol. as an inhibitor of Rac family small GTPases, placing Rac1 in an inert and inactive state and then impairing Rac1-mediated functions in vivo. Our work suggests that EHT 1864 selectively inhibits Rac1 downstream signaling and cellular transformation by a novel mechanism involving guanine nucleotide displacement. This chapter provides the details for some of the biochem. and biol. methods used to characterize the mode of action of EHT 1864 on Rac1 and its impact on Rac1-dependent cellular functions.

IT 754240-09-0, EHT1864
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(biochem. and biol. methods may be useful to characterize Rho GTPase specificity and mechanism of action of EHT 1864 on Rac1 and its impact on Rac1-dependent cellular function in mouse)

RN 754240-09-0 HCAPLUS

CN 4H-Pyran-4-one, 2-(4-morpholinylmethyl)-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]-, hydrochloride (1:2) (CA INDEX NAME)



L4 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1368320 HCAPLUS
DOCUMENT NUMBER: 148:232138
TITLE: Specificity and Mechanism of Action of EHT 1864, a Novel Small Molecule Inhibitor of Rac Family Small GTPases

AUTHOR(S): Shutes, Adam; Onesto, Cercina; Picard, Virginie; Leblond, Bertrand; Schweighoffer, Fabien; Der, Channing J.
CORPORATE SOURCE: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, 27599, USA
SOURCE: Journal of Biological Chemistry (2007), 282(49), 35666-35678
CODEN: JBCHA3; ISSN: 0021-9258
PUBLISHER: American Society for Biochemistry and Molecular Biology
DOCUMENT TYPE: Journal
LANGUAGE: English

AB There is now considerable exptl. evidence that aberrant activation of Rho family small GTPases promotes the uncontrolled proliferation, invasion, and metastatic properties of human cancer cells. Therefore, there is considerable interest in the development of small mol. inhibitors of Rho GTPase function. However, to date, most efforts have focused on inhibitors that indirectly block Rho GTPase function, by targeting either enzymes involved in post-translational processing or downstream protein kinase effectors. We recently determined that the EHT 1864 small mol. can inhibit Rac function in vivo. In this study, we evaluated the biol. and biochem. specificities and biochem. mechanism of action of EHT 1864. We determined that EHT 1864 specifically inhibited Rac1-dependent platelet-derived growth factor-induced lamellipodia formation. Furthermore, our biochem. analyses with recombinant Rac proteins found that EHT 1864 possesses high affinity binding to Rac1, as well as the related Rac1b, Rac2, and Rac3 isoforms, and this association promoted the loss of bound nucleotide, inhibiting both guanine nucleotide association and Tiaml Rac guanine nucleotide exchange factor-stimulated exchange factor activity in vitro. EHT 1864 therefore places Rac in an inert and inactive state, preventing its engagement with downstream effectors. Finally, we evaluated the ability of EHT 1864 to block Rac-dependent growth transformation, and we determined that EHT 1864 potently blocked transformation caused by constitutively activated Rac1, as well as Rac-dependent transformation caused by Tiaml or Ras. Taken together, our results suggest that EHT 1864 selectively inhibits Rac downstream signaling and transformation by a novel mechanism involving guanine nucleotide displacement.

IT 754240-09-0, EHT 1864
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EHT 1864 specifically inhibits Rac1-dependent platelet-derived growth factor-induced lamellipodia formation)

RN 754240-09-0 HCAPLUS

CN 4H-Pyran-4-one, 2-(4-morpholinylmethyl)-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]-, hydrochloride (1:2) (CA INDEX NAME)



REFERENCE COUNT: 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1191062 HCAPLUS
DOCUMENT NUMBER: 144:68139
TITLE: RAC1 Inhibition Targets Amyloid Precursor Protein Processing by γ-Secretase and Decreases Aβ Production in Vitro and in Vivo
AUTHOR(S): Desire, Laurent; Bourdin, Jerome; Loiseau, Nadia; Peillon, Helene; Picard, Virginie; De Oliveira, Catherine; Bachelot, Florence; Leblond, Bertrand; Taverne, Thierry; Beausoleil, Eric; Lacombe, Sandrine; Drouin, Dominique; Schweighoffer, Fabien
CORPORATE SOURCE: Exonhit Therapeutics, Paris, 75013, Fr.
SOURCE: Journal of Biological Chemistry (2005), 280(45), 37516-37525
CODEN: JBCHA3; ISSN: 0021-9258
PUBLISHER: American Society for Biochemistry and Molecular Biology
DOCUMENT TYPE: Journal
LANGUAGE: English

AB β-Amyloid peptides (Aβ) that form the senile plaques of Alzheimer disease consist mainly of 40- and 42-amino acid (Aβ 40 and Aβ 42) peptides generated from the cleavage of the amyloid precursor protein (APP). Generation of Aβ involves β-secretase and γ-secretase activities and is regulated by membrane trafficking of the proteins involved in Aβ production Here we describe a new small mol., EHT 1864, which blocks the Rac1 signaling pathways. In vitro, EHT 1864 blocks Aβ 40 and Aβ 42 production but does not impact sAPPα levels and does not inhibit β-secretase. Rather, EHT 1864 modulates APP processing at the level of γ-secretase to prevent

Aβ 40 and Aβ 42 generation. This effect does not result from a direct inhibition of the γ-secretase activity and is specific for APP cleavage, since EHT 1864 does not affect Notch cleavage. In vivo, EHT 1864 significantly reduces Aβ 40 and Aβ 42 levels in guinea pig brains at a threshold that is compatible with delaying plaque accumulation and/or clearing the existing plaque in brain. EHT 1864 is the first derivative of a new chemical series that consists of candidates for inhibiting Aβ formation in the brain of AD patients. Our findings represent the first pharmacol. validation of Rac1 signaling as a target for developing novel therapies for Alzheimer disease.

IT 754240-09-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(EHT 1864; EHT 1864 blocked Aβ1-40 and Aβ1-42 production)

RN 754240-09-0 HCAPLUS

CN 4H-Pyran-4-one, 2-(4-morpholinylmethyl)-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]-, hydrochloride (1:2) (CA INDEX NAME)



REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:740320 HCAPLUS

DOCUMENT NUMBER: 141:260557

TITLE: Preparation of novel antiproliferative and antiangiogenic agents, in particular quinoline-derivatized pyranones, for treating cell proliferative diseases, retinopathies and arthritis

INVENTOR(S): Leblond, Bertrand; Petit, Silvere; Picard, Virginie; Taverne, Thierry; Schweighoffer, Fabien

PATENT ASSIGNEE(S): Exonhit Therapeutics Sa, Fr.

SOURCE: PCT Int. Appl., 156 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004076445	A2	20040910	WO 2004-IB926		20040227
WO 2004076445	A3	20050106			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI					
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
EP 1471063	A1	20041027	EP 2003-290490		20030228
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
AU 2004215577	A1	20040910	AU 2004-215577		20040227
CA 2516239	A1	20040910	CA 2004-2516239		20040227
EP 1597253	A2	20051123	EP 2004-715422		20040227
EP 1597253	B1	20060809			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
CN 1747952	A	20060315	CN 2004-80003820		20040227
JP 2006519221	T	20060824	JP 2006-502497		20040227
AT 335734	T	20060915	AT 2004-715422		20040227
US 20060183749	A1	20060817	US 2005-541328		20050830

PRIORITY APPLN. INFO.: EP 2003-290490 A 20030228
WO 2004-IB926 W 20040227

OTHER SOURCE(S): MARPAT 141:260557
GI



I



II

AB Title compds. I [wherein R1 = [(tetrahydropyran-2-yl)oxy]methyl, CH2-B, (morpholin-4-yl)methyl, pyrrolidin-1-ylmethyl, etc.; B = halo, OH, OCH2OMe, OCH2OCH2CH2OMe, OSO2-alkyl, OTBDMS; R2 = H, alk(en)yl; X, Y = independently O, S, NH and derivs.; A = quinolin-4-yl, quinolin-8-yl, benzo[b]thiophen-7-yl, quinazolin-4-yl; Z = (CH2)n, optionally interrupted by a heteroatom, C(:O) or aryldialkyl, especially xylenyl, group; n = 1-10; their tautomers, optical and geometrical isomers, racemates, salts, hydrates and mixts.] were prepared as antiproliferative agents and angiogenesis inhibitors. Nine biol. assays are given. For example, II was prepared, in 2 steps, from pyranone III, 1,4-dibromobutane, and 7-(trifluoromethyl)-4-quinolinethiol. In an in vitro cell viability assay, selected I showed an IC50 < 4μM and < 9 μM against HCT116 and MDA-MB-231 tumoral cell lines, demonstrating their cytostatic mode of action. I are useful for treating various diseases associated with abnormal cell proliferation, including cancer, especially leukemia, or associated with unregulated angiogenesis including growth and metastasis of solid tumors, ocular diseases, especially retinopathies, or arthritis.

IT 754240-09-0P, 5-[[5-[7-(Trifluoromethyl)quinolin-4-ylthio]pentyl]oxy]-2-(morpholinomethyl)-4H-pyran-4-one dihydrochloride 754240-17-0P, 5-[[5-[7-(Trifluoromethyl)quinolin-4-ylthio]pentyl]oxy]-2-[(4-methylpiperazin-1-yl)methyl]-4H-pyran-4-one trihydrochloride 754240-19-2P, 5-[[5-[7-(Trifluoromethyl)quinolin-4-ylthio]pentyl]oxy]-2-[(piperazin-1-yl)methyl]-4H-pyran-4-one trihydrochloride
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of novel antiproliferative and antiangiogenic agents, in particular quinoline-derivatized pyranones, for treating cell proliferative diseases, retinopathies and arthritis)

RN 754240-09-0 HCAPLUS

CN 4H-Pyran-4-one, 2-(4-morpholinylmethyl)-5-[[5-[[7-(trifluoromethyl)-4-

quinolinyl]thio]pentyl]oxy]-, hydrochloride (1:2) (CA INDEX NAME)



RN 754240-17-0 HCAPLUS
CN 4H-Pyran-4-one, 2-[(4-methyl-1-piperazinyl)methyl]-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]-, hydrochloride (1:3) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

● 3 HCl

RN 754240-19-2 HCAPLUS
CN 4H-Pyran-4-one, 2-(1-piperazinylmethyl)-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]-, hydrochloride (1:3) (CA INDEX NAME)



IT 754239-59-3P, 2-Hydroxymethyl-5-[[5-[7-(trifluoromethyl)quinolin-4-ylsulfanyl]pentyl]oxy]-4H-pyran-4-one 754240-15-8P, tert-Butyl 4-[[5-[[5-[7-(trifluoromethyl)quinolin-4-ylthio]pentyl]oxy]-4-oxo-4H-pyran-2-yl]methyl]piperazine-1-carboxylate 754240-16-9P, tert-Butyl 4-[[5-[[5-(7-chloroquinolin-4-yloxy)pentyl]oxy]-4-oxo-4H-pyran-2-yl]methyl]piperazine-1-carboxylate
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of novel antiproliferative and antiangiogenic agents, in particular quinoline-derivatized pyranones, for treating cell proliferative diseases, retinopathies and arthritis)

RN 754239-59-3 HCAPLUS

CN 4H-Pyran-4-one, 2-(hydroxymethyl)-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]- (CA INDEX NAME)



RN 754240-15-8 HCAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[4-oxo-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]-4H-pyran-2-yl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 754240-16-9 HCAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[5-[[5-[(7-chloro-4-quinolinyl)oxy]pentyl]oxy]-4-oxo-4H-pyran-2-yl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT 754239-47-9P, 5-[[5-(6-Fluoro-2-methylquinolin-4-yloxy)pentyl]oxy]-2-[[(tetrahydropyran-2-yl)oxy]methyl]-4H-pyran-4-one 754239-48-0P

, 5-[[5-(6-Fluoro-2-trifluoromethylquinolin-4-yloxy)pentyl]oxy]-2-[[(tetrahydropyran-2-yl)oxy]methyl]-4H-pyran-4-one 754239-49-1P, 5-[[5-(7-Propylquinolin-8-yloxy)pentyl]oxy]-2-[[(tetrahydropyran-2-yl)oxy]methyl]-4H-pyran-4-one 754239-50-4P, 5-[5-[(Benzo[b]thiophen-7-yl)oxy]pentyloxy]-2-[[(tetrahydropyran-2-yl)oxy]methyl]-4H-pyran-4-one 754239-51-5P, 2-[[(Tetrahydropyran-2-yl)oxy]methyl]-5-[5-[[7-(trifluoromethyl)quinolin-4-yl]sulfanyl]pentyloxy]-4H-pyran-4-one 754239-53-7P, 2-[[(Tetrahydropyran-2-yl)oxy]methyl]-5-[4-[[7-(trifluoromethyl)quinolin-4-yl]sulfanyl]butoxy]-4H-pyran-4-one 754239-55-9P, 2-[[(Tetrahydropyran-2-yl)oxy]methyl]-5-[6-[[7-(trifluoromethyl)quinolin-4-yl]sulfanyl]hexyloxy]-4H-pyran-4-one 754239-56-0P, 2-Hydroxymethyl-5-[[5-(7-trifluoromethylquinolin-4-ylsulfanyl)pentyl]oxy]-4H-pyran-4-one hydrochloride 754239-60-6P, 2-[(Methoxymethoxy)methyl]-5-[[5-[7-(trifluoromethyl)quinolin-4-ylsulfanyl]pentyl]oxy]-4H-pyran-4-one 754239-62-8P, 2-Chloromethyl-5-[[5-(7-trifluoromethylquinolin-4-ylsulfanyl)pentyl]oxy]-4H-pyran-4-one 754239-63-9P, 2-(4-Methylpiperazin-1-ylmethyl)-5-[[5-[[7-(trifluoromethyl)quinolin-4-yl]sulfanyl]pentyl]oxy]-4H-pyran-4-one 754239-64-0P, 2-[(Morpholin-4-yl)methyl]-5-[[5-[[7-(trifluoromethyl)quinolin-4-yl]sulfanyl]pentyl]oxy]-4H-pyran-4-one 754239-66-2P, 5-[[7-[7-(Trifluoromethyl)quinolin-4-ylthio]heptyl]oxy]-2-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-4H-pyran-4-one 754239-68-4P, 5-[[8-[7-(Trifluoromethyl)quinolin-4-ylthio]octyl]oxy]-2-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-4H-pyran-4-one 754239-80-0P, 5-[[5-[7-(Trifluoromethyl)quinolin-4-ylthio]pentyl]oxy]-2-[(piperidin-1-yl)methyl]-4H-pyran-4-one 754239-81-1P, 5-[[5-[7-(Trifluoromethyl)quinolin-4-ylthio]pentyl]oxy]-2-(thiomorpholinomethyl)-4H-pyran-4-one 754239-82-2P, 2-[(Diethylamino)methyl]-5-[[5-[7-(trifluoromethyl)quinolin-4-ylthio]pentyl]oxy]-4H-pyran-4-one 754239-83-3P, 5-[[5-[6-(Trifluoromethyl)quinolin-4-yloxy]pentyl]oxy]-2-(morpholinomethyl)-4H-pyran-4-one 754239-84-4P, 5-[[5-[7-(Trifluoromethyl)quinolin-4-yloxy]pentyl]oxy]-2-[(4-methylpiperazin-1-yl)methyl]-4H-pyran-4-one 754239-85-5P, 5-[[5-[7-(Trifluoromethyl)quinolin-4-yloxy]pentyl]oxy]-2-(morpholinomethyl)-4H-pyran-4-one 754239-86-6P, 4-[[5-[[6-(4-Methylpiperazin-1-ylmethyl)-4-oxo-4H-pyran-3-Yl]oxy]pentyl]oxy]-7-trifluoromethylquinoline-3-carboxylic acid ethyl ester 754239-87-7P, 4-[[5-[[6-[(Morpholin-4-yl)methyl]-4-oxo-4H-pyran-3-yl]oxy]pentyl]oxy]-7-trifluoromethylquinoline-3-carboxylic acid ethyl ester 754239-88-8P, 5-[[5-[8-(Trifluoromethyl)quinolin-4-yloxy]pentyl]oxy]-2-[(4-methylpiperazin-1-yl)methyl]-4H-pyran-4-one 754239-89-9P, 5-[[5-[8-(Trifluoromethyl)quinolin-4-yloxy]pentyl]oxy]-2-(morpholinomethyl)-4H-pyran-4-one 754239-90-2P, 5-[[5-(Quinazolin-4-yloxy)pentyl]oxy]-2-[(pyrrolidin-1-yl)methyl]-4H-pyran-4-one 754239-91-3P, 5-[[5-(Quinazolin-4-yloxy)pentyl]oxy]-2-(morpholinomethyl)-4H-pyran-4-one 754239-92-4P, 5-[[5-(Quinazolin-4-yloxy)pentyl]oxy]-2-[(4-methylpiperazin-1-yl)methyl]-4H-pyran-4-one 754239-93-5P, 5-[[5-[7-(Trifluoromethyl)quinolin-4-ylthio]pentyl]oxy]-2-(fluoromethyl)-4H-pyran-4-one 754240-07-8P, 5-[2-[7-(Trifluoromethyl)quinolin-4-ylthio]ethoxy]-2-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-4H-pyran-4-one 754240-08-9P, 5-[2-[7-(Trifluoromethyl)quinolin-4-yloxy]ethoxy]-2-(morpholinomethyl)-4H-pyran-4-one 754240-18-1P, 5-[[5-(7-Chloroquinolin-4-yloxy)pentyl]oxy]-2-[(piperazin-1-yl)methyl]-4H-pyran-4-one trihydrochloride 754240-21-6P, 5-[[5-[7-

(Trifluoromethyl)quinolin-4-ylthio]pentyl]oxy]-2-[(4-acetylpiperazin-1-yl)methyl]-4H-pyran-4-one 754240-22-7P, 4-[[5-[[5-[7-(Trifluoromethyl)quinolin-4-ylthio]pentyl]oxy]-4-oxo-4H-pyran-2-yl]methyl]-N,N-diethylpiperazine-1-carboxamide 754240-23-8P, 5-[[5-[7-(Trifluoromethyl)quinolin-4-ylthio]pentyl]oxy]-2-[[4-(pivaloyl)piperazin-1-yl]methyl]-4H-pyran-4-one 754240-24-9P, 4-[[5-[[5-[7-(Trifluoromethyl)quinolin-4-ylthio]pentyl]oxy]-4-oxo-4H-pyran-2-yl]methyl]-N,N-diisopropylpiperazine-1-carboxamide 754240-25-0P, 5-[[5-[7-(Trifluoromethyl)quinolin-4-ylthio]pentyl]oxy]-2-[(4-Methylsulfonylpiperazin-1-yl)methyl]-4H-pyran-4-one 754240-26-1P, 4-[[5-[[5-[7-(Trifluoromethyl)quinolin-4-ylthio]pentyl]oxy]-4-oxo-4H-pyran-2-yl]methyl]-N-tert-butylpiperazine-1-carboxamide 754240-27-2P, 4-[[5-[[5-[7-(Trifluoromethyl)quinolin-4-ylthio]pentyl]oxy]-4-oxo-4H-pyran-2-yl]methyl]-N-methylpiperazine-1-carboxamide 754240-28-3P, 5-[[5-(7-Chloroquinolin-4-yloxy)pentyl]oxy]-2-[(piperazin-1-yl)methyl]-4H-pyran-4-one
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of novel antiproliferative and antiangiogenic agents, in particular quinoline-derivatized pyranones, for treating cell proliferative diseases, retinopathies and arthritis)

RN 754239-47-9 HCAPLUS

CN 4H-Pyran-4-one, 5-[[5-[(6-fluoro-2-methyl-4-quinolinyl)oxy]pentyl]oxy]-2-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 754239-48-0 HCAPLUS
CN 4H-Pyran-4-one, 5-[[5-[[6-fluoro-2-(trifluoromethyl)-4-quinolinyl]oxy]pentyl]oxy]-2-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 754239-49-1 HCAPLUS
CN 4H-Pyran-4-one, 5-[[5-[(7-propyl-8-quinolinyl)oxy]pentyl]oxy]-2-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 754239-50-4 HCAPLUS
CN 4H-Pyran-4-one, 5-[[5-(benzo[b]thien-7-yloxy)pentyl]oxy]-2-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 754239-51-5 HCAPLUS
CN 4H-Pyran-4-one, 2-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-5-[[5-[(7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 754239-53-7 HCAPLUS
CN 4H-Pyran-4-one, 2-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-5-[4-[[7-(trifluoromethyl)-4-quinolinyl]thio]butoxy]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 754239-55-9 HCAPLUS
CN 4H-Pyran-4-one, 2-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-5-[[6-[[7-(trifluoromethyl)-4-quinolinyl]thio]hexyl]oxy]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 754239-56-0 HCAPLUS
CN 4H-Pyran-4-one, 2-(hydroxymethyl)-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 754239-60-6 HCAPLUS
CN 4H-Pyran-4-one, 2-[(methoxymethoxy)methyl]-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]- (CA INDEX NAME)



RN 754239-62-8 HCAPLUS
CN 4H-Pyran-4-one, 2-(chloromethyl)-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]- (CA INDEX NAME)



RN 754239-63-9 HCAPLUS
CN 4H-Pyran-4-one, 2-[(4-methyl-1-piperazinyl)methyl]-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

Me

RN 754239-64-0 HCAPLUS
CN 4H-Pyran-4-one, 2-(4-morpholinylmethyl)-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]- (CA INDEX NAME)



RN 754239-66-2 HCAPLUS
CN 4H-Pyran-4-one, 2-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-5-[[7-[[7-(trifluoromethyl)-4-quinolinyl]thio]heptyl]oxy]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 754239-68-4 HCAPLUS
CN 4H-Pyran-4-one, 2-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-5-[[8-[(7-(trifluoromethyl)-4-quinolinyl]thio]octyl]oxy]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 754239-80-0 HCAPLUS
CN 4H-Pyran-4-one, 2-(1-piperidinylmethyl)-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]- (CA INDEX NAME)



RN 754239-81-1 HCAPLUS
CN 4H-Pyran-4-one, 2-(4-thiomorpholinylmethyl)-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]- (CA INDEX NAME)



RN 754239-82-2 HCAPLUS
CN 4H-Pyran-4-one, 2-[(diethylamino)methyl]-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]- (CA INDEX NAME)



RN 754239-83-3 HCAPLUS
CN 4H-Pyran-4-one, 2-(4-morpholinylmethyl)-5-[[5-[[6-(trifluoromethyl)-4-quinolinyl]oxy]pentyl]oxy]- (CA INDEX NAME)



RN 754239-84-4 HCAPLUS
CN 4H-Pyran-4-one, 2-[(4-methyl-1-piperazinyl)methyl]-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]oxy]pentyl]oxy]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 754239-85-5 HCAPLUS
CN 4H-Pyran-4-one, 2-(4-morpholinylmethyl)-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]oxy]pentyl]oxy]- (CA INDEX NAME)



RN 754239-86-6 HCAPLUS
CN 3-Quinolinecarboxylic acid, 4-[[5-[[6-[(4-methyl-1-piperazinyl)methyl]-4-oxo-4H-pyran-3-yl]oxy]pentyl]oxy]-7-(trifluoromethyl)-, ethyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

Me

RN 754239-87-7 HCAPLUS
CN 3-Quinolinecarboxylic acid, 4-[[5-[[6-(4-morpholinylmethyl)-4-oxo-4H-pyran-3-yl]oxy]pentyl]oxy]-7-(trifluoromethyl)-, ethyl ester (CA INDEX NAME)



RN 754239-88-8 HCAPLUS
CN 4H-Pyran-4-one, 2-[(4-methyl-1-piperazinyl)methyl]-5-[[5-[[8-(trifluoromethyl)-4-quinolinyl]oxy]pentyl]oxy]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 754239-89-9 HCAPLUS
CN 4H-Pyran-4-one, 2-(4-morpholinylmethyl)-5-[[5-[[8-(trifluoromethyl)-4-quinolinyl]oxy]pentyl]oxy]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 754239-90-2 HCAPLUS
CN 4H-Pyran-4-one, 2-(1-pyrrolidinylmethyl)-5-[[5-(4-quinazolinyloxy)pentyl]oxy]- (CA INDEX NAME)



RN 754239-91-3 HCAPLUS
CN 4H-Pyran-4-one, 2-(4-morpholinylmethyl)-5-[[5-(4-quinazolinyloxy)pentyl]oxy]- (CA INDEX NAME)



RN 754239-92-4 HCAPLUS
CN 4H-Pyran-4-one, 2-[(4-methyl-1-piperazinyl)methyl]-5-[[5-(4-quinazolinyloxy)pentyl]oxy]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 754239-93-5 HCAPLUS
CN 4H-Pyran-4-one, 2-(fluoromethyl)-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]- (CA INDEX NAME)



RN 754240-07-8 HCAPLUS
CN 4H-Pyran-4-one, 2-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-5-[2-[[7-(trifluoromethyl)-4-quinolinyl]thio]ethoxy]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 754240-08-9 HCAPLUS
CN 4H-Pyran-4-one, 2-(4-morpholinylmethyl)-5-[2-[[7-(trifluoromethyl)-4-quinolinyl]oxy]ethoxy]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 754240-18-1 HCAPLUS
CN 4H-Pyran-4-one, 5-[[5-[(7-chloro-4-quinolinyl)oxy]pentyl]oxy]-2-(1-piperazinylmethyl)-, hydrochloride (1:3) (CA INDEX NAME)



RN 754240-21-6 HCAPLUS
CN 4H-Pyran-4-one, 2-[(4-acetyl-1-piperazinyl)methyl]-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 754240-22-7 HCAPLUS
CN 1-Piperazinecarboxamide, N,N-diethyl-4-[[4-oxo-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]-4H-pyran-2-yl]methyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 754240-23-8 HCAPLUS
CN 4H-Pyran-4-one, 2-[[4-(2,2-dimethyl-1-oxopropyl)-1-piperazinyl]methyl]-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 754240-24-9 HCAPLUS
CN 1-Piperazinecarboxamide, N,N-bis(1-methylethyl)-4-[[4-oxo-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]-4H-pyran-2-yl]methyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 754240-25-0 HCAPLUS
CN 4H-Pyran-4-one, 2-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 754240-26-1 HCAPLUS
CN 1-Piperazinecarboxamide, N-(1,1-dimethylethyl)-4-[[4-oxo-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]-4H-pyran-2-yl]methyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 754240-27-2 HCAPLUS
CN 1-Piperazinecarboxamide, N-methyl-4-[[4-oxo-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]-4H-pyran-2-yl]methyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 754240-28-3 HCAPLUS
CN 4H-Pyran-4-one, 5-[[5-[(7-chloro-4-quinolinyl)oxy]pentyl]oxy]-2-(1-piperazinylmethyl)- (CA INDEX NAME)



IT 754239-58-2P, 2-[(tert-Butyldimethylsilanyloxy)methyl]-5-[[5-[[7-(trifluoromethyl)quinolin-4-yl]sulfanyl]pentyl]oxy]-4H-pyran-4-one 754239-61-7P, Methanesulfonic acid [4-oxo-5-[[5-(7-trifluoromethylquinolin-4-ylsulfanyl)pentyl]oxy]-4H-pyran-2-yl]methyl ester 754239-70-8P, 5-[[5-[6-(Trifluoromethyl)quinolin-4-yloxy]pentyl]oxy]-2-(hydroxymethyl)-4H-pyran-4-one 754239-71-9P, 5-[[5-[7-(Trifluoromethyl)quinolin-4-yloxy]pentyl]oxy]-2-(hydroxymethyl)-4H-pyran-4-one 754239-72-0P, 4-[5-[(6-Hydroxymethyl-4-oxo-4H-pyran-3-yl)oxy]pentyloxy]-7-trifluoromethylquinoline-3-carboxylic acid ethyl ester 754239-73-1P, 5-[[5-[8-(Trifluoromethyl)quinolin-4-yloxy]pentyl]oxy]-2-(hydroxymethyl)-4H-pyran-4-one 754239-74-2P, 5-[[5-(Quinazolin-4-yloxy)pentyl]oxy]-2-(hydroxymethyl)-4H-pyran-4-one 754239-75-3P, [5-[[5-[6-(Trifluoromethyl)quinolin-4-yloxy]pentyl]oxy]-4-oxo-4H-pyran-2-yl]methyl methanesulfonate 754239-76-4P, [5-[[5-[7-(Trifluoromethyl)quinolin-4-yloxy]pentyl]oxy]-4-oxo-4H-pyran-2-yl]methyl methanesulfonate 754239-77-5P, 4-[[5-[[6-[(Methanesulfonyloxy)methyl]-4-oxo-4H-pyran-3-yl]oxy]pentyl]oxy]-7-trifluoromethylquinoline-3-carboxylic acid ethyl ester 754239-78-6P, [5-[[5-[8-(Trifluoromethyl)quinolin-4-yloxy]pentyl]oxy]-4-oxo-4H-pyran-2-yl]methyl methanesulfonate 754239-79-7P, [5-[[5-(Quinazolin-4-yloxy)pentyl]oxy]-4-oxo-4H-pyran-2-yl]methyl methanesulfonate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of novel antiproliferative and antiangiogenic agents, in particular quinoline-derivatized pyranones, for treating cell proliferative diseases, retinopathies and arthritis)

RN 754239-58-2 HCAPLUS

CN 4H-Pyran-4-one, 2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]- (CA INDEX NAME)



RN 754239-61-7 HCAPLUS
CN 4H-Pyran-4-one, 2-[[(methylsulfonyl)oxy]methyl]-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]- (CA INDEX NAME)



RN 754239-70-8 HCAPLUS
CN 4H-Pyran-4-one, 2-(hydroxymethyl)-5-[[5-[[6-(trifluoromethyl)-4-quinolinyl]oxy]pentyl]oxy]- (CA INDEX NAME)



RN 754239-71-9 HCAPLUS
CN 4H-Pyran-4-one, 2-(hydroxymethyl)-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]oxy]pentyl]oxy]- (CA INDEX NAME)



RN 754239-72-0 HCAPLUS
CN 3-Quinolinecarboxylic acid, 4-[[5-[[6-(hydroxymethyl)-4-oxo-4H-pyran-3-yl]oxy]pentyl]oxy]-7-(trifluoromethyl)-, ethyl ester (CA INDEX NAME)



RN 754239-73-1 HCAPLUS
CN 4H-Pyran-4-one, 2-(hydroxymethyl)-5-[[5-[[8-(trifluoromethyl)-4-quinolinyl]oxy]pentyl]oxy]- (CA INDEX NAME)



RN 754239-74-2 HCAPLUS
CN 4H-Pyran-4-one, 2-(hydroxymethyl)-5-[[5-(4-quinazolinyloxy)pentyl]oxy]- (CA INDEX NAME)



RN 754239-75-3 HCAPLUS
CN 4H-Pyran-4-one, 2-[[(methylsulfonyl)oxy]methyl]-5-[[5-[[6-(trifluoromethyl)-4-quinolinyl]oxy]pentyl]oxy]- (CA INDEX NAME)



RN 754239-76-4 HCAPLUS
CN 4H-Pyran-4-one, 2-[[(methylsulfonyl)oxy]methyl]-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]oxy]pentyl]oxy]- (CA INDEX NAME)



RN 754239-77-5 HCAPLUS
CN 3-Quinolinecarboxylic acid, 4-[[5-[[6-[[(methylsulfonyl)oxy]methyl]-4-oxo-4H-pyran-3-yl]oxy]pentyl]oxy]-7-(trifluoromethyl)-, ethyl ester (CA INDEX NAME)



RN 754239-78-6 HCAPLUS
CN 4H-Pyran-4-one, 2-[[(methylsulfonyl)oxy]methyl]-5-[[5-[[8-(trifluoromethyl)-4-quinolinyl]oxy]pentyl]oxy]- (CA INDEX NAME)



RN 754239-79-7 HCAPLUS
CN 4H-Pyran-4-one, 2-[[(methylsulfonyl)oxy]methyl]-5-[[5-(4-quinazolinyloxy)pentyl]oxy]- (CA INDEX NAME)



IT 754240-20-5, 5-[[5-[7-(Trifluoromethyl)quinolin-4-ylthio]pentyl]oxy]-2-[(piperazin-1-yl)methyl]-4H-pyran-4-one
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of novel antiproliferative and antiangiogenic agents, in particular quinoline-derivatized pyranones, for treating cell proliferative diseases, retinopathies and arthritis)
RN 754240-20-5 HCAPLUS
CN 4H-Pyran-4-one, 2-(1-piperazinylmethyl)-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]- (CA INDEX NAME)



L4 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	1995:608133 HCAPLUS
DOCUMENT NUMBER:	123:83751
ORIGINAL REFERENCE NO.:	123:15005a,15008a
TITLE:	Mechanism-Based Development of New Antimalarials: Synthesis of Derivatives of Artemisinin Attached to Iron Chelators
AUTHOR(S):	Kamchonwongpaisan, Sumalee; Paitayatat, Sumpan; Thebtaranonth, Yodhathai; Wilairat, Prapin; Yuthavong, Yongyuth
CORPORATE SOURCE:	Faculty of Science, Mahidol University, Bangkok, 10400, Thailand
SOURCE:	Journal of Medicinal Chemistry (1995), 38(13), 2311-16 CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER:	American Chemical Society
DOCUMENT TYPE:	Journal
LANGUAGE:	English

GI



I

AB Various derivs. of artemisinin covalently linked to iron chelators, e.g. I, were synthesized, and their antimalarial activities were evaluated. Although results show no indication that the presence of an iron chelator in the vicinity of artemisinin potentiates its action, the linked compds. prepared still retain comparable activities to that of artemisinin.

IT 165068-36-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(mechanism-based development of new antimalarials, synthesis of derivs. of artemisinin attached to iron chelators)

RN 165068-36-0 HCAPLUS

CN 4H-Pyran-4-one, 3-[3-[(decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl)oxy]propoxy]-6-(hydroxymethyl)-, [3R-(3α,5aβ,6β,8aβ,9α,10α,12β,12aR*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	46.08	224.65

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE ENTRY TOTAL SESSION
CA SUBSCRIBER PRICE -4.00 -4.00

FILE 'REGISTRY' ENTERED AT 10:46:19 ON 04 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 2 AUG 2008 HIGHEST RN 1037774-47-2
DICTIONARY FILE UPDATES: 2 AUG 2008 HIGHEST RN 1037774-47-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10541328a.str

chain nodes :
7 9 10 12 15
ring nodes :
1 2 3 4 5 6
chain bonds :
3-12 4-7 9-10 9-12 10-15

ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
1-2 1-6 2-3 3-4 3-12 4-5 4-7 5-6 9-10 9-12 10-15
isolated ring systems :
containing 1 :

G1:O,S,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 9:CLASS 10:Atom 12:CLASS
15:Atom

L6 STRUCTURE UPLOADED

=> d l6
L6 HAS NO ANSWERS
L6 STR



G1 O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> s l6
SAMPLE SEARCH INITIATED 10:46:38 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 28332 TO ITERATE

7.1% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 556571 TO 576709
PROJECTED ANSWERS: 0 TO 0

L7 0 SEA SSS SAM L6

```
=> s l6 sss full
FULL SEARCH INITIATED 10:46:44 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   575864 TO ITERATE

100.0% PROCESSED   575864 ITERATIONS                          85 ANSWERS
SEARCH TIME: 00.00.08

L8           85 SEA SSS FUL L6

=>
Uploading C:\Program Files\Stnexp\Queries\10541328b.str
```

```
chain nodes :
7  9  10  12
ring nodes :
1  2  3  4  5  6
chain bonds :
3-12  4-7  9-10  9-12
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6
exact/norm bonds :
1-2  1-6  2-3  3-4  3-12  4-5  4-7  5-6  9-10  9-12
isolated ring systems :
containing 1 :


G1:O,S,N

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  9:CLASS  10:Atom  12:CLASS



L9       STRUCTURE UPLOADED

=> d l9
L9 HAS NO ANSWERS
```

L9 STR



G1 O,S,N

Structure attributes must be viewed using STN Express query preparation.

```
=> s l9
SAMPLE SEARCH INITIATED 10:47:49 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    28332 TO ITERATE

  7.1% PROCESSED     2000 ITERATIONS                                1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       556571 TO   576709
PROJECTED ANSWERS:             58 TO      508

L10           1 SEA SSS SAM L9

=> s l9 sss full
FULL SEARCH INITIATED 10:47:55 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   575864 TO ITERATE

100.0% PROCESSED   575864 ITERATIONS                          218 ANSWERS
SEARCH TIME: 00.00.04

L11         218 SEA SSS FUL L9

=> FIL HCAPLUS
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                              357.18     581.83

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                 ENTRY    SESSION
CA SUBSCRIBER PRICE                                0.00      -4.00

FILE 'HCAPLUS' ENTERED AT 10:48:03 ON 04 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 4 Aug 2008 VOL 149 ISS 6
FILE LAST UPDATED: 3 Aug 2008 (20080803/ED)

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

```
=> d his

     (FILE 'HOME' ENTERED AT 10:41:20 ON 04 AUG 2008)

     FILE 'REGISTRY' ENTERED AT 10:41:35 ON 04 AUG 2008
L1              STRUCTURE UPLOADED
L2            0 S L1
L3           69 S L1 SSS FULL

     FILE 'HCAPLUS' ENTERED AT 10:42:11 ON 04 AUG 2008
L4            5 S L3
L5            1 S L4 AND PY<=2003

     FILE 'REGISTRY' ENTERED AT 10:46:19 ON 04 AUG 2008
L6              STRUCTURE UPLOADED
L7            0 S L6
L8           85 S L6 SSS FULL
L9              STRUCTURE UPLOADED
L10           1 S L9
L11         218 S L9 SSS FULL

     FILE 'HCAPLUS' ENTERED AT 10:48:03 ON 04 AUG 2008

=> s l8
L12           6 L8

=> s l11
L13          23 L11

=> s l12 and py<=2003
      24005635 PY<=2003
L14           1 L12 AND PY<=2003

=> s l13 and py<=2003
      24005635 PY<=2003
```

```
L15         17 L13 AND PY<=2003

=> s l15 and p/dt
      6298780 P/DT
L16         11 L15 AND P/DT

=> s l16 and us/pc
      1822860 US/PC
L17          5 L16 AND US/PC

=> d l12 ibib abs hitstr tot

L12  ANSWER 1 OF 6  HCAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:        2008:622524  HCAPLUS
TITLE:                   Characterization of EHT 1864, a novel small molecule
                         inhibitor of Rac family small GTPases
AUTHOR(S):               Onesto, Cercina; Shutes, Adam; Picard, Virginie;
                         Schweighoffer, Fabien; Der, Channing J.
CORPORATE SOURCE:        Lineberger Comprehensive Cancer Center, Department of
                         Pharmacology, University of North Carolina at Chapel
                         Hill, Chapel Hill, NC, USA
SOURCE:                  Methods in Enzymology (2008), 439(Small GTPAses in
                         Disease, Part B), 111-129
                         CODEN: MENZAU; ISSN: 0076-6879
PUBLISHER:               Elsevier
DOCUMENT TYPE:           Journal; General Review
LANGUAGE:                English
AB   A review.  There is now considerable exptl. evidence that aberrant
     activation of Rho family small GTPases promotes uncontrolled
     proliferation, invasion, and metastatic properties of human cancer cells.
     Therefore, there is considerable interest in the development of small mol.
     inhibitors of Rho GTPase function.  However, to date, most efforts have
     focused on inhibitors that block Rho GTPase function indirectly, either by
     targeting enzymes involved in post-translational processing or downstream
     protein kinase effectors.  We have reported the identification and
     characterization of the EHT 1864 small mol. as an inhibitor of Rac family
     small GTPases, placing Rac1 in an inert and inactive state and then
     impairing Rac1-mediated functions in vivo.  Our work suggests that EHT
     1864 selectively inhibits Rac1 downstream signaling and cellular
     transformation by a novel mechanism involving guanine nucleotide
     displacement.  This chapter provides the details for some of the biochem.
     and biol. methods used to characterize the mode of action of EHT 1864 on
     Rac1 and its impact on Rac1-dependent cellular functions.
IT   754240-09-0, EHT1864
     RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU
     (Therapeutic use); BIOL (Biological study); USES (Uses)
        (biochem. and biol. methods may be useful to characterize Rho GTPase
        specificity and mechanism of action of EHT 1864 on Rac1 and its impact
        on Rac1-dependent cellular function in mouse)
RN   754240-09-0  HCAPLUS
CN   4H-Pyran-4-one, 2-(4-morpholinylmethyl)-5-[[5-[[7-(trifluoromethyl)-4-
     quinolinyl]thio]pentyl]oxy]-, hydrochloride (1:2)  (CA INDEX NAME)
```



L12 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1368320 HCAPLUS
DOCUMENT NUMBER: 148:232138
TITLE: Specificity and Mechanism of Action of EHT 1864, a Novel Small Molecule Inhibitor of Rac Family Small GTPases
AUTHOR(S): Shutes, Adam; Onesto, Cercina; Picard, Virginie; Leblond, Bertrand; Schweighoffer, Fabien; Der, Channing J.
CORPORATE SOURCE: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, 27599, USA
SOURCE: Journal of Biological Chemistry (2007), 282(49), 35666-35678
CODEN: JBCHA3; ISSN: 0021-9258
PUBLISHER: American Society for Biochemistry and Molecular Biology
DOCUMENT TYPE: Journal
LANGUAGE: English
AB There is now considerable exptl. evidence that aberrant activation of Rho family small GTPases promotes the uncontrolled proliferation, invasion, and metastatic properties of human cancer cells. Therefore, there is considerable interest in the development of small mol. inhibitors of Rho GTPase function. However, to date, most efforts have focused on inhibitors that indirectly block Rho GTPase function, by targeting either enzymes involved in post-translational processing or downstream protein kinase effectors. We recently determined that the EHT 1864 small mol. can inhibit Rac function in vivo. In this study, we evaluated the biol. and biochem. specificities and biochem. mechanism of action of EHT 1864. We determined that EHT 1864 specifically inhibited Rac1-dependent platelet-derived growth factor-induced lamellipodia formation. Furthermore, our biochem. analyses with recombinant Rac proteins found that EHT 1864 possesses high

affinity binding to Rac1, as well as the related Rac1b, Rac2, and Rac3 isoforms, and this association promoted the loss of bound nucleotide, inhibiting both guanine nucleotide association and Tiam1 Rac guanine nucleotide exchange factor-stimulated exchange factor activity in vitro. EHT 1864 therefore places Rac in an inert and inactive state, preventing its engagement with downstream effectors. Finally, we evaluated the ability of EHT 1864 to block Rac-dependent growth transformation, and we determined that EHT 1864 potently blocked transformation caused by constitutively activated Rac1, as well as Rac-dependent transformation caused by Tiam1 or Ras. Taken together, our results suggest that EHT 1864 selectively inhibits Rac downstream signaling and transformation by a novel mechanism involving guanine nucleotide displacement.

IT 754240-09-0, EHT 1864
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EHT 1864 specifically inhibits Rac1-dependent platelet-derived growth factor-induced lamellipodia formation)

RN 754240-09-0 HCAPLUS

CN 4H-Pyran-4-one, 2-(4-morpholinylmethyl)-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]-, hydrochloride (1:2) (CA INDEX NAME)



REFERENCE COUNT: 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:525951 HCAPLUS

DOCUMENT NUMBER: 147:143245

TITLE: Chemotherapy of leishmaniasis. Part V: Synthesis and in vitro bioevaluation of novel pyridinone derivatives

AUTHOR(S): Pandey, Susmita; Suryawanshi, S. N.; Nishi; Goyal, Neena; Gupta, Suman

CORPORATE SOURCE: Division of Medicinal Chemistry, Central Drug Research Institute, Lucknow, Uttar Pradesh, 226001, India

SOURCE: European Journal of Medicinal Chemistry (2007), 42(5), 669-674
CODEN: EJMCA5; ISSN: 0223-5234
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 147:143245

AB Alkylation of 3-hydroxy-2-methyl-4H-pyran-4-one with 1,5-dibromopentane gave dimeric γ-pyrone (2), which was recyclized with substituted anilines or cyclohexylamine to yield 1,1'-diaryl-2,2'-dimethyl-3,3'-pentamethylenedioxy-4,4'-bipyridinones (3a,b, d-j; aryl = 2,6-Me2C6H3, 2,3-Me2C6H3, 4-MeOC6H4, Ph, PhCH2, 4-FC6H4, 4-ClC6H4, 4-NO2C6H4, 2-MeOC6H4) and 1,1'-dicyclohexyl derivative (3c), together with the corresponding pyridinone-pyrone derivs., 1-Ar-2-methyl-3-[5-(2-methyl-4-oxo-4H-pyran-3-yloxy)pentyloxy]-4(4H)-pyridinones (4a-j, same Ar). The novel 2-substituted pyridinone derivs. were screened towards in vitro for their activity against leishmania antipromastigote and antiamastigote activity profile, exhibiting good activity in some cases (3a, 3b; aryl = 2,6-Me2C6H3, 2,3-Me2C6H3, 4i, 4j, Ar = 4-NO2C6H4, 2-MeOC6H4).

IT 943737-55-1P 943737-57-3P 943737-59-5P
943737-61-9P 943737-63-1P 943737-64-2P
943737-66-4P 943737-68-6P 943737-70-0P
943737-72-2P 943737-74-4P 943737-76-6P
943737-77-7P 943737-79-9P
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antileishmaniasis activity; preparation of pentamethylenedioxy-bridged bis-4-pyridinones and pyridinone-pyrones as antimicrobial agents against leishmaniasis)

RN 943737-55-1 HCAPLUS
CN 4(1H)-Pyridinone, 3,3'-[1,5-pentanediylbis(oxy)]bis[1-(2,6-dimethylphenyl)-2-methyl- (CA INDEX NAME)



RN 943737-57-3 HCAPLUS
CN 4(1H)-Pyridinone, 3,3'-[1,5-pentanediylbis(oxy)]bis[1-(2,3-dimethylphenyl)-2-methyl- (CA INDEX NAME)



RN 943737-59-5 HCAPLUS
CN 4(1H)-Pyridinone, 3,3'-[1,5-pentanediylbis(oxy)]bis[1-cyclohexyl-2-methyl-
(CA INDEX NAME)



RN 943737-61-9 HCAPLUS
CN 4(1H)-Pyridinone, 3,3'-[1,5-pentanediylbis(oxy)]bis[1-(4-methoxyphenyl)-2-
methyl- (CA INDEX NAME)



RN 943737-63-1 HCAPLUS
CN 4(1H)-Pyridinone, 3,3'-[1,5-pentanediylbis(oxy)]bis[2-methyl-1-phenyl-
(CA INDEX NAME)



RN 943737-64-2 HCAPLUS
CN 4(1H)-Pyridinone, 3,3'-[1,5-pentanediylbis(oxy)]bis[2-methyl-1-
(phenylmethyl)- (CA INDEX NAME)



RN 943737-66-4 HCAPLUS
CN 4(1H)-Pyridinone, 3,3'-[1,5-pentanediylbis(oxy)]bis[1-(4-fluorophenyl)-2-methyl- (CA INDEX NAME)



RN 943737-68-6 HCAPLUS
CN 4(1H)-Pyridinone, 1-(2,6-dimethylphenyl)-2-methyl-3-[[5-[(2-methyl-4-oxo-4H-pyran-3-yl)oxy]pentyl]oxy]- (CA INDEX NAME)



RN 943737-70-0 HCAPLUS
CN 4(1H)-Pyridinone, 1-cyclohexyl-2-methyl-3-[[5-[(2-methyl-4-oxo-4H-pyran-3-yl)oxy]pentyl]oxy]- (CA INDEX NAME)



RN 943737-72-2 HCAPLUS
CN 4(1H)-Pyridinone, 2-methyl-3-[[5-[(2-methyl-4-oxo-4H-pyran-3-yl)oxy]pentyl]oxy]-1-(phenylmethyl)- (CA INDEX NAME)



RN 943737-74-4 HCAPLUS
CN 4(1H)-Pyridinone, 1-(4-fluorophenyl)-2-methyl-3-[[5-[(2-methyl-4-oxo-4H-pyran-3-yl)oxy]pentyl]oxy]- (CA INDEX NAME)



RN 943737-76-6 HCAPLUS
CN 4(1H)-Pyridinone, 1-(4-chlorophenyl)-2-methyl-3-[[5-[(2-methyl-4-oxo-4H-pyran-3-yl)oxy]pentyl]oxy]- (CA INDEX NAME)



RN 943737-77-7 HCAPLUS
CN 4(1H)-Pyridinone, 2-methyl-3-[[5-[(2-methyl-4-oxo-4H-pyran-3-yl)oxy]pentyl]oxy]-1-(4-nitrophenyl)- (CA INDEX NAME)



RN 943737-79-9 HCAPLUS
CN 4(1H)-Pyridinone, 1-(2-methoxyphenyl)-2-methyl-3-[[5-[(2-methyl-4-oxo-4H-pyran-3-yl)oxy]pentyl]oxy]- (CA INDEX NAME)



IT 943737-53-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pentamethylenedioxy-bridged bis-4-pyridinones and pyridinone-pyrones as antimicrobial agents against leishmaniasis)
RN 943737-53-9 HCAPLUS
CN 4H-Pyran-4-one, 3,3'-[1,5-pentanediylbis(oxy)]bis[2-methyl- (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1191062 HCAPLUS
DOCUMENT NUMBER: 144:68139
TITLE: RAC1 Inhibition Targets Amyloid Precursor Protein Processing by γ-Secretase and Decreases Aβ Production in Vitro and in Vivo
AUTHOR(S): Desire, Laurent; Bourdin, Jerome; Loiseau, Nadia; Peillon, Helene; Picard, Virginie; De Oliveira, Catherine; Bachelot, Florence; Leblond, Bertrand; Taverne, Thierry; Beausoleil, Eric; Lacombe, Sandrine; Drouin, Dominique; Schweighoffer, Fabien
CORPORATE SOURCE: Exonhit Therapeutics, Paris, 75013, Fr.
SOURCE: Journal of Biological Chemistry (2005), 280(45), 37516-37525
CODEN: JBCHA3; ISSN: 0021-9258
PUBLISHER: American Society for Biochemistry and Molecular Biology
DOCUMENT TYPE: Journal
LANGUAGE: English
AB β-Amyloid peptides (Aβ) that form the senile plaques of Alzheimer disease consist mainly of 40- and 42-amino acid (Aβ 40 and Aβ 42) peptides generated from the cleavage of the amyloid precursor protein (APP). Generation of Aβ involves β-secretase and γ-secretase activities and is regulated by membrane trafficking of the proteins involved in Aβ production Here we describe a new small mol., EHT 1864, which blocks the Rac1 signaling pathways. In vitro, EHT 1864 blocks Aβ 40 and Aβ 42 production but does not impact

sAPPα levels and does not inhibit β-secretase. Rather, EHT 1864 modulates APP processing at the level of γ-secretase to prevent Aβ 40 and Aβ 42 generation. This effect does not result from a direct inhibition of the γ-secretase activity and is specific for APP cleavage, since EHT 1864 does not affect Notch cleavage. In vivo, EHT 1864 significantly reduces Aβ 40 and Aβ 42 levels in guinea pig brains at a threshold that is compatible with delaying plaque accumulation and/or clearing the existing plaque in brain. EHT 1864 is the first derivative of a new chemical series that consists of candidates for inhibiting Aβ formation in the brain of AD patients. Our findings represent the first pharmacol. validation of Rac1 signaling as a target for developing novel therapies for Alzheimer disease.

IT 754240-09-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(EHT 1864; EHT 1864 blocked Aβ1-40 and Aβ1-42 production)

RN 754240-09-0 HCAPLUS

CN 4H-Pyran-4-one, 2-(4-morpholinylmethyl)-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]-, hydrochloride (1:2) (CA INDEX NAME)



REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:740320 HCAPLUS

DOCUMENT NUMBER: 141:260557

TITLE: Preparation of novel antiproliferative and antiangiogenic agents, in particular quinoline-derivatized pyranones, for treating cell proliferative diseases, retinopathies and arthritis

INVENTOR(S): Leblond, Bertrand; Petit, Silvere; Picard, Virginie; Taverne, Thierry; Schweighoffer, Fabien

PATENT ASSIGNEE(S): Exonhit Therapeutics Sa, Fr.
SOURCE: PCT Int. Appl., 156 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004076445	A2	20040910	WO 2004-IB926	20040227
WO 2004076445	A3	20050106		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1471063	A1	20041027	EP 2003-290490	20030228
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AU 2004215577	A1	20040910	AU 2004-215577	20040227
CA 2516239	A1	20040910	CA 2004-2516239	20040227
EP 1597253	A2	20051123	EP 2004-715422	20040227
EP 1597253	B1	20060809		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1747952	A	20060315	CN 2004-80003820	20040227
JP 2006519221	T	20060824	JP 2006-502497	20040227
AT 335734	T	20060915	AT 2004-715422	20040227
US 20060183749	A1	20060817	US 2005-541328	20050830

PRIORITY APPLN. INFO.: EP 2003-290490 A 20030228
WO 2004-IB926 W 20040227

OTHER SOURCE(S): MARPAT 141:260557
GI



I



II

AB Title compds. I [wherein R1 = [(tetrahydropyran-2-yl)oxy]methyl, CH2-B, (morpholin-4-yl)methyl, pyrrolidin-1-ylmethyl, etc.; B = halo, OH, OCH2OMe, OCH2OCH2CH2OMe, OSO2-alkyl, OTBDMS; R2 = H, alk(en)yl; X, Y = independently O, S, NH and derivs.; A = quinolin-4-yl, quinolin-8-yl, benzo[b]thiophen-7-yl, quinazolin-4-yl; Z = (CH2)n, optionally interrupted by a heteroatom, C(:O) or aryldialkyl, especially xylenyl, group; n = 1-10; their tautomers, optical and geometrical isomers, racemates, salts, hydrates and mixts.] were prepared as antiproliferative agents and angiogenesis inhibitors. Nine biol. assays are given. For example, II was prepared, in 2 steps, from pyranone III, 1,4-dibromobutane, and 7-(trifluoromethyl)-4-quinolinethiol. In an in vitro cell viability assay, selected I showed an IC50 < 4μM and < 9 μM against HCT116 and MDA-MB-231 tumoral cell lines, demonstrating their cytostatic mode of action. I are useful for treating various diseases associated with abnormal cell proliferation, including cancer, especially leukemia, or associated with unregulated angiogenesis including growth and metastasis of solid tumors, ocular diseases, especially retinopathies, or arthritis.

IT 754240-09-0P, 5-[[5-[7-(Trifluoromethyl)quinolin-4-ylthio]pentyl]oxy]-2-(morpholinomethyl)-4H-pyran-4-one dihydrochloride 754240-17-0P, 5-[[5-[7-(Trifluoromethyl)quinolin-4-ylthio]pentyl]oxy]-2-[(4-methylpiperazin-1-yl)methyl]-4H-pyran-4-one trihydrochloride 754240-19-2P, 5-[[5-[7-(Trifluoromethyl)quinolin-4-ylthio]pentyl]oxy]-2-[(piperazin-1-yl)methyl]-4H-pyran-4-one trihydrochloride
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of novel antiproliferative and antiangiogenic agents, in particular quinoline-derivatized pyranones, for treating cell proliferative diseases, retinopathies and arthritis)

RN 754240-09-0 HCAPLUS

CN 4H-Pyran-4-one, 2-(4-morpholinylmethyl)-5-[[5-[[7-(trifluoromethyl)-4-

quinolinyl]thio]pentyl]oxy]-, hydrochloride (1:2) (CA INDEX NAME)



RN 754240-17-0 HCAPLUS
CN 4H-Pyran-4-one, 2-[(4-methyl-1-piperazinyl)methyl]-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]-, hydrochloride (1:3) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

● 3 HCl

RN 754240-19-2 HCAPLUS
CN 4H-Pyran-4-one, 2-(1-piperazinylmethyl)-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]-, hydrochloride (1:3) (CA INDEX NAME)



IT 754239-59-3P, 2-Hydroxymethyl-5-[[5-[7-(trifluoromethyl)quinolin-4-ylsulfanyl]pentyl]oxy]-4H-pyran-4-one 754240-15-8P, tert-Butyl 4-[[5-[[5-[7-(trifluoromethyl)quinolin-4-ylthio]pentyl]oxy]-4-oxo-4H-pyran-2-yl]methyl]piperazine-1-carboxylate 754240-16-9P, tert-Butyl 4-[[5-[[5-(7-chloroquinolin-4-yloxy)pentyl]oxy]-4-oxo-4H-pyran-2-yl]methyl]piperazine-1-carboxylate
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of novel antiproliferative and antiangiogenic agents, in particular quinoline-derivatized pyranones, for treating cell proliferative diseases, retinopathies and arthritis)

RN 754239-59-3 HCAPLUS

CN 4H-Pyran-4-one, 2-(hydroxymethyl)-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]- (CA INDEX NAME)



RN 754240-15-8 HCAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[4-oxo-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]-4H-pyran-2-yl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 754240-16-9 HCAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[5-[[5-[(7-chloro-4-quinolinyl)oxy]pentyl]oxy]-4-oxo-4H-pyran-2-yl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT 754239-47-9P, 5-[[5-(6-Fluoro-2-methylquinolin-4-yloxy)pentyl]oxy]-2-[[(tetrahydropyran-2-yl)oxy]methyl]-4H-pyran-4-one 754239-48-0P

, 5-[[5-(6-Fluoro-2-trifluoromethylquinolin-4-yloxy)pentyl]oxy]-2-[[(tetrahydropyran-2-yl)oxy]methyl]-4H-pyran-4-one 754239-49-1P, 5-[[5-(7-Propylquinolin-8-yloxy)pentyl]oxy]-2-[[(tetrahydropyran-2-yl)oxy]methyl]-4H-pyran-4-one 754239-50-4P, 5-[5-[(Benzo[b]thiophen-7-yl)oxy]pentyloxy]-2-[[(tetrahydropyran-2-yl)oxy]methyl]-4H-pyran-4-one 754239-51-5P, 2-[[(Tetrahydropyran-2-yl)oxy]methyl]-5-[5-[[7-(trifluoromethyl)quinolin-4-yl]sulfanyl]pentyloxy]-4H-pyran-4-one 754239-53-7P, 2-[[Tetrahydropyran-2-yl)oxy]methyl]-5-[4-[[7-(trifluoromethyl)quinolin-4-yl]sulfanyl]butoxy]-4H-pyran-4-one 754239-55-9P, 2-[[(Tetrahydropyran-2-yl)oxy]methyl]-5-[6-[[7-(trifluoromethyl)quinolin-4-yl]sulfanyl]hexyloxy]-4H-pyran-4-one 754239-56-0P, 2-Hydroxymethyl-5-[[5-(7-trifluoromethylquinolin-4-ylsulfanyl)pentyl]oxy]-4H-pyran-4-one hydrochloride 754239-60-6P, 2-[(Methoxymethoxy)methyl]-5-[[5-[7-(trifluoromethyl)quinolin-4-ylsulfanyl]pentyl]oxy]-4H-pyran-4-one 754239-62-8P, 2-Chloromethyl-5-[[5-(7-trifluoromethylquinolin-4-ylsulfanyl)pentyl]oxy]-4H-pyran-4-one 754239-63-9P, 2-(4-Methylpiperazin-1-ylmethyl)-5-[[5-[[7-(trifluoromethyl)quinolin-4-yl]sulfanyl]pentyl]oxy]-4H-pyran-4-one 754239-64-0P, 2-[(Morpholin-4-yl)methyl]-5-[[5-[[7-(trifluoromethyl)quinolin-4-yl]sulfanyl]pentyl]oxy]-4H-pyran-4-one 754239-66-2P, 5-[[7-[7-(Trifluoromethyl)quinolin-4-ylthio]heptyl]oxy]-2-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-4H-pyran-4-one 754239-68-4P, 5-[[8-[7-(Trifluoromethyl)quinolin-4-ylthio]octyl]oxy]-2-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-4H-pyran-4-one 754239-80-0P, 5-[[5-[7-(Trifluoromethyl)quinolin-4-ylthio]pentyl]oxy]-2-[(piperidin-1-yl)methyl]-4H-pyran-4-one 754239-81-1P, 5-[[5-[7-(Trifluoromethyl)quinolin-4-ylthio]pentyl]oxy]-2-(thiomorpholinomethyl)-4H-pyran-4-one 754239-82-2P, 2-[(Diethylamino)methyl]-5-[[5-[7-(trifluoromethyl)quinolin-4-ylthio]pentyl]oxy]-4H-pyran-4-one 754239-83-3P, 5-[[5-[6-(Trifluoromethyl)quinolin-4-yloxy]pentyl]oxy]-2-(morpholinomethyl)-4H-pyran-4-one 754239-84-4P, 5-[[5-[7-(Trifluoromethyl)quinolin-4-yloxy]pentyl]oxy]-2-[(4-methylpiperazin-1-yl)methyl]-4H-pyran-4-one 754239-85-5P, 5-[[5-[7-(Trifluoromethyl)quinolin-4-yloxy]pentyl]oxy]-2-(morpholinomethyl)-4H-pyran-4-one 754239-86-6P, 4-[[5-[[6-(4-Methylpiperazin-1-ylmethyl)-4-oxo-4H-pyran-3-Yl]oxy]pentyl]oxy]-7-trifluoromethylquinoline-3-carboxylic acid ethyl ester 754239-87-7P, 4-[[5-[[6-[(Morpholin-4-yl)methyl]-4-oxo-4H-pyran-3-yl]oxy]pentyl]oxy]-7-trifluoromethylquinoline-3-carboxylic acid ethyl ester 754239-88-8P, 5-[[5-[8-(Trifluoromethyl)quinolin-4-yloxy]pentyl]oxy]-2-[(4-methylpiperazin-1-yl)methyl]-4H-pyran-4-one 754239-89-9P, 5-[[5-[8-(Trifluoromethyl)quinolin-4-yloxy]pentyl]oxy]-2-(morpholinomethyl)-4H-pyran-4-one 754239-90-2P, 5-[[5-(Quinazolin-4-yloxy)pentyl]oxy]-2-[(pyrrolidin-1-yl)methyl]-4H-pyran-4-one 754239-91-3P, 5-[[5-(Quinazolin-4-yloxy)pentyl]oxy]-2-(morpholinomethyl)-4H-pyran-4-one 754239-92-4P, 5-[[5-(Quinazolin-4-yloxy)pentyl]oxy]-2-[(4-methylpiperazin-1-yl)methyl]-4H-pyran-4-one 754239-93-5P, 5-[[5-[7-(Trifluoromethyl)quinolin-4-ylthio]pentyl]oxy]-2-(fluoromethyl)-4H-pyran-4-one 754240-07-8P, 5-[2-[7-(Trifluoromethyl)quinolin-4-ylthio]ethoxy]-2-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-4H-pyran-4-one 754240-08-9P, 5-[2-[7-(Trifluoromethyl)quinolin-4-yloxy]ethoxy]-2-(morpholinomethyl)-4H-pyran-4-one 754240-18-1P, 5-[[5-(7-Chloroquinolin-4-yloxy)pentyl]oxy]-2-[(piperazin-1-yl)methyl]-4H-pyran-4-one trihydrochloride 754240-21-6P, 5-[[5-[7-

(Trifluoromethyl)quinolin-4-ylthio]pentyl]oxy]-2-[(4-acetylpiperazin-1-yl)methyl]-4H-pyran-4-one 754240-22-7P, 4-[[5-[[5-[7-(Trifluoromethyl)quinolin-4-ylthio]pentyl]oxy]-4-oxo-4H-pyran-2-yl]methyl]-N,N-diethylpiperazine-1-carboxamide 754240-23-8P, 5-[[5-[7-(Trifluoromethyl)quinolin-4-ylthio]pentyl]oxy]-2-[[4-(pivaloyl)piperazin-1-yl]methyl]-4H-pyran-4-one 754240-24-9P, 4-[[5-[[5-[7-(Trifluoromethyl)quinolin-4-ylthio]pentyl]oxy]-4-oxo-4H-pyran-2-yl]methyl]-N,N-diisopropylpiperazine-1-carboxamide 754240-25-0P, 5-[[5-[7-(Trifluoromethyl)quinolin-4-ylthio]pentyl]oxy]-2-[(4-Methylsulfonylpiperazin-1-yl)methyl]-4H-pyran-4-one 754240-26-1P, 4-[[5-[[5-[7-(Trifluoromethyl)quinolin-4-ylthio]pentyl]oxy]-4-oxo-4H-pyran-2-yl]methyl]-N-tert-butylpiperazine-1-carboxamide 754240-27-2P, 4-[[5-[[5-[7-(Trifluoromethyl)quinolin-4-ylthio]pentyl]oxy]-4-oxo-4H-pyran-2-yl]methyl]-N-methylpiperazine-1-carboxamide 754240-28-3P, 5-[[5-(7-Chloroquinolin-4-yloxy)pentyl]oxy]-2-[(piperazin-1-yl)methyl]-4H-pyran-4-one
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of novel antiproliferative and antiangiogenic agents, in particular quinoline-derivatized pyranones, for treating cell proliferative diseases, retinopathies and arthritis)

RN 754239-47-9 HCAPLUS

CN 4H-Pyran-4-one, 5-[[5-[(6-fluoro-2-methyl-4-quinolinyl)oxy]pentyl]oxy]-2-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 754239-48-0 HCAPLUS
CN 4H-Pyran-4-one, 5-[[5-[[6-fluoro-2-(trifluoromethyl)-4-quinolinyl]oxy]pentyl]oxy]-2-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 754239-49-1 HCAPLUS
CN 4H-Pyran-4-one, 5-[[5-[(7-propyl-8-quinolinyl)oxy]pentyl]oxy]-2-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 754239-50-4 HCAPLUS
CN 4H-Pyran-4-one, 5-[[5-(benzo[b]thien-7-yloxy)pentyl]oxy]-2-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 754239-51-5 HCAPLUS
CN 4H-Pyran-4-one, 2-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-5-[[5-[(7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 754239-53-7 HCAPLUS
CN 4H-Pyran-4-one, 2-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-5-[4-[[7-(trifluoromethyl)-4-quinolinyl]thio]butoxy]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 754239-55-9 HCAPLUS
CN 4H-Pyran-4-one, 2-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-5-[[6-[[7-(trifluoromethyl)-4-quinolinyl]thio]hexyl]oxy]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 754239-56-0 HCAPLUS
CN 4H-Pyran-4-one, 2-(hydroxymethyl)-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 754239-60-6 HCAPLUS
CN 4H-Pyran-4-one, 2-[(methoxymethoxy)methyl]-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]- (CA INDEX NAME)



RN 754239-62-8 HCAPLUS
CN 4H-Pyran-4-one, 2-(chloromethyl)-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]- (CA INDEX NAME)



RN 754239-63-9 HCAPLUS
CN 4H-Pyran-4-one, 2-[(4-methyl-1-piperazinyl)methyl]-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

Me

RN 754239-64-0 HCAPLUS
CN 4H-Pyran-4-one, 2-(4-morpholinylmethyl)-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]- (CA INDEX NAME)



RN 754239-66-2 HCAPLUS
CN 4H-Pyran-4-one, 2-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-5-[[7-[[7-(trifluoromethyl)-4-quinolinyl]thio]heptyl]oxy]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 754239-68-4 HCAPLUS
CN 4H-Pyran-4-one, 2-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-5-[[8-[(7-(trifluoromethyl)-4-quinolinyl]thio]octyl]oxy]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 754239-80-0 HCAPLUS
CN 4H-Pyran-4-one, 2-(1-piperidinylmethyl)-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]- (CA INDEX NAME)



RN 754239-81-1 HCAPLUS
CN 4H-Pyran-4-one, 2-(4-thiomorpholinylmethyl)-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]- (CA INDEX NAME)



RN 754239-82-2 HCAPLUS
CN 4H-Pyran-4-one, 2-[(diethylamino)methyl]-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]- (CA INDEX NAME)



RN 754239-83-3 HCAPLUS
CN 4H-Pyran-4-one, 2-(4-morpholinylmethyl)-5-[[5-[[6-(trifluoromethyl)-4-quinolinyl]oxy]pentyl]oxy]- (CA INDEX NAME)



RN 754239-84-4 HCAPLUS
CN 4H-Pyran-4-one, 2-[(4-methyl-1-piperazinyl)methyl]-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]oxy]pentyl]oxy]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 754239-85-5 HCAPLUS
CN 4H-Pyran-4-one, 2-(4-morpholinylmethyl)-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]oxy]pentyl]oxy]- (CA INDEX NAME)



RN 754239-86-6 HCAPLUS
CN 3-Quinolinecarboxylic acid, 4-[[5-[[6-[(4-methyl-1-piperazinyl)methyl]-4-oxo-4H-pyran-3-yl]oxy]pentyl]oxy]-7-(trifluoromethyl)-, ethyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

Me

RN 754239-87-7 HCAPLUS
CN 3-Quinolinecarboxylic acid, 4-[[5-[[6-(4-morpholinylmethyl)-4-oxo-4H-pyran-3-yl]oxy]pentyl]oxy]-7-(trifluoromethyl)-, ethyl ester (CA INDEX NAME)



RN 754239-88-8 HCAPLUS
CN 4H-Pyran-4-one, 2-[(4-methyl-1-piperazinyl)methyl]-5-[[5-[[8-(trifluoromethyl)-4-quinolinyl]oxy]pentyl]oxy]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 754239-89-9 HCAPLUS
CN 4H-Pyran-4-one, 2-(4-morpholinylmethyl)-5-[[5-[[8-(trifluoromethyl)-4-quinolinyl]oxy]pentyl]oxy]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 754239-90-2 HCAPLUS
CN 4H-Pyran-4-one, 2-(1-pyrrolidinylmethyl)-5-[[5-(4-quinazolinyloxy)pentyl]oxy]- (CA INDEX NAME)



RN 754239-91-3 HCAPLUS
CN 4H-Pyran-4-one, 2-(4-morpholinylmethyl)-5-[[5-(4-quinazolinyloxy)pentyl]oxy]- (CA INDEX NAME)



RN 754239-92-4 HCAPLUS
CN 4H-Pyran-4-one, 2-[(4-methyl-1-piperazinyl)methyl]-5-[[5-(4-quinazolinyloxy)pentyl]oxy]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 754239-93-5 HCAPLUS
CN 4H-Pyran-4-one, 2-(fluoromethyl)-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]- (CA INDEX NAME)



RN 754240-07-8 HCAPLUS
CN 4H-Pyran-4-one, 2-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-5-[2-[[7-(trifluoromethyl)-4-quinolinyl]thio]ethoxy]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 754240-08-9 HCAPLUS
CN 4H-Pyran-4-one, 2-(4-morpholinylmethyl)-5-[2-[[7-(trifluoromethyl)-4-quinolinyl]oxy]ethoxy]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 754240-18-1 HCAPLUS
CN 4H-Pyran-4-one, 5-[[5-[(7-chloro-4-quinolinyl)oxy]pentyl]oxy]-2-(1-piperazinylmethyl)-, hydrochloride (1:3) (CA INDEX NAME)



RN 754240-21-6 HCAPLUS
CN 4H-Pyran-4-one, 2-[(4-acetyl-1-piperazinyl)methyl]-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 754240-22-7 HCAPLUS
CN 1-Piperazinecarboxamide, N,N-diethyl-4-[[4-oxo-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]-4H-pyran-2-yl]methyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 754240-23-8 HCAPLUS
CN 4H-Pyran-4-one, 2-[[4-(2,2-dimethyl-1-oxopropyl)-1-piperazinyl]methyl]-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 754240-24-9 HCAPLUS
CN 1-Piperazinecarboxamide, N,N-bis(1-methylethyl)-4-[[4-oxo-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]-4H-pyran-2-yl]methyl]-(CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 754240-25-0 HCAPLUS
CN 4H-Pyran-4-one, 2-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 754240-26-1 HCAPLUS
CN 1-Piperazinecarboxamide, N-(1,1-dimethylethyl)-4-[[4-oxo-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]-4H-pyran-2-yl]methyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 754240-27-2 HCAPLUS
CN 1-Piperazinecarboxamide, N-methyl-4-[[4-oxo-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]-4H-pyran-2-yl]methyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 754240-28-3 HCAPLUS
CN 4H-Pyran-4-one, 5-[[5-[(7-chloro-4-quinolinyl)oxy]pentyl]oxy]-2-(1-piperazinylmethyl)- (CA INDEX NAME)



IT 754239-58-2P, 2-[(tert-Butyldimethylsilanyloxy)methyl]-5-[[5-[[7-(trifluoromethyl)quinolin-4-yl]sulfanyl]pentyl]oxy]-4H-pyran-4-one 754239-61-7P, Methanesulfonic acid [4-oxo-5-[[5-(7-trifluoromethylquinolin-4-ylsulfanyl)pentyl]oxy]-4H-pyran-2-yl]methyl ester 754239-70-8P, 5-[[5-[6-(Trifluoromethyl)quinolin-4-yloxy]pentyl]oxy]-2-(hydroxymethyl)-4H-pyran-4-one 754239-71-9P, 5-[[5-[7-(Trifluoromethyl)quinolin-4-yloxy]pentyl]oxy]-2-(hydroxymethyl)-4H-pyran-4-one 754239-72-0P, 4-[5-[(6-Hydroxymethyl-4-oxo-4H-pyran-3-yl)oxy]pentyloxy]-7-trifluoromethylquinoline-3-carboxylic acid ethyl ester 754239-73-1P, 5-[[5-[8-(Trifluoromethyl)quinolin-4-yloxy]pentyl]oxy]-2-(hydroxymethyl)-4H-pyran-4-one 754239-74-2P, 5-[[5-(Quinazolin-4-yloxy)pentyl]oxy]-2-(hydroxymethyl)-4H-pyran-4-one 754239-75-3P, [5-[[5-[6-(Trifluoromethyl)quinolin-4-yloxy]pentyl]oxy]-4-oxo-4H-pyran-2-yl]methyl methanesulfonate 754239-76-4P, [5-[[5-[7-(Trifluoromethyl)quinolin-4-yloxy]pentyl]oxy]-4-oxo-4H-pyran-2-yl]methyl methanesulfonate 754239-77-5P, 4-[[5-[[6-[(Methanesulfonyloxy)methyl]-4-oxo-4H-pyran-3-yl]oxy]pentyl]oxy]-7-trifluoromethylquinoline-3-carboxylic acid ethyl ester 754239-78-6P, [5-[[5-[8-(Trifluoromethyl)quinolin-4-yloxy]pentyl]oxy]-4-oxo-4H-pyran-2-yl]methyl methanesulfonate 754239-79-7P, [5-[[5-(Quinazolin-4-yloxy)pentyl]oxy]-4-oxo-4H-pyran-2-yl]methyl methanesulfonate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of novel antiproliferative and antiangiogenic agents, in particular quinoline-derivatized pyranones, for treating cell proliferative diseases, retinopathies and arthritis)

RN 754239-58-2 HCAPLUS

CN 4H-Pyran-4-one, 2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]- (CA INDEX NAME)



RN 754239-61-7 HCAPLUS
CN 4H-Pyran-4-one, 2-[[(methylsulfonyl)oxy]methyl]-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]- (CA INDEX NAME)



RN 754239-70-8 HCAPLUS
CN 4H-Pyran-4-one, 2-(hydroxymethyl)-5-[[5-[[6-(trifluoromethyl)-4-quinolinyl]oxy]pentyl]oxy]- (CA INDEX NAME)



RN 754239-71-9 HCAPLUS
CN 4H-Pyran-4-one, 2-(hydroxymethyl)-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]oxy]pentyl]oxy]- (CA INDEX NAME)



RN 754239-72-0 HCAPLUS
CN 3-Quinolinecarboxylic acid, 4-[[5-[[6-(hydroxymethyl)-4-oxo-4H-pyran-3-yl]oxy]pentyl]oxy]-7-(trifluoromethyl)-, ethyl ester (CA INDEX NAME)



RN 754239-73-1 HCAPLUS
CN 4H-Pyran-4-one, 2-(hydroxymethyl)-5-[[5-[[8-(trifluoromethyl)-4-quinolinyl]oxy]pentyl]oxy]- (CA INDEX NAME)



RN 754239-74-2 HCAPLUS
CN 4H-Pyran-4-one, 2-(hydroxymethyl)-5-[[5-(4-quinazolinyloxy)pentyl]oxy]- (CA INDEX NAME)



RN 754239-75-3 HCAPLUS
CN 4H-Pyran-4-one, 2-[[(methylsulfonyl)oxy]methyl]-5-[[5-[[6-(trifluoromethyl)-4-quinolinyl]oxy]pentyl]oxy]- (CA INDEX NAME)



RN 754239-76-4 HCAPLUS
CN 4H-Pyran-4-one, 2-[[(methylsulfonyl)oxy]methyl]-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]oxy]pentyl]oxy]- (CA INDEX NAME)



RN 754239-77-5 HCAPLUS
CN 3-Quinolinecarboxylic acid, 4-[[5-[[6-[[(methylsulfonyl)oxy]methyl]-4-oxo-4H-pyran-3-yl]oxy]pentyl]oxy]-7-(trifluoromethyl)-, ethyl ester (CA INDEX NAME)



RN 754239-78-6 HCAPLUS
CN 4H-Pyran-4-one, 2-[[(methylsulfonyl)oxy]methyl]-5-[[5-[[8-(trifluoromethyl)-4-quinolinyl]oxy]pentyl]oxy]- (CA INDEX NAME)



RN 754239-79-7 HCAPLUS
CN 4H-Pyran-4-one, 2-[[(methylsulfonyl)oxy]methyl]-5-[[5-(4-quinazolinyloxy)pentyl]oxy]- (CA INDEX NAME)



IT 754240-20-5, 5-[[5-[7-(Trifluoromethyl)quinolin-4-ylthio]pentyl]oxy]-2-[(piperazin-1-yl)methyl]-4H-pyran-4-one
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of novel antiproliferative and antiangiogenic agents, in particular quinoline-derivatized pyranones, for treating cell proliferative diseases, retinopathies and arthritis)
RN 754240-20-5 HCAPLUS
CN 4H-Pyran-4-one, 2-(1-piperazinylmethyl)-5-[[5-[[7-(trifluoromethyl)-4-quinolinyl]thio]pentyl]oxy]- (CA INDEX NAME)



L12 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1995:608133 HCAPLUS
DOCUMENT NUMBER: 123:83751
ORIGINAL REFERENCE NO.: 123:15005a,15008a
TITLE: Mechanism-Based Development of New Antimalarials: Synthesis of Derivatives of Artemisinin Attached to Iron Chelators
AUTHOR(S): Kamchonwongpaisan, Sumalee; Paitayatat, Sumpan; Thebtaranonth, Yodhathai; Wilairat, Prapin; Yuthavong, Yongyuth
CORPORATE SOURCE: Faculty of Science, Mahidol University, Bangkok, 10400, Thailand
SOURCE: Journal of Medicinal Chemistry (1995), 38(13), 2311-16
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB Various derivs. of artemisinin covalently linked to iron chelators, e.g. I, were synthesized, and their antimalarial activities were evaluated. Although results show no indication that the presence of an iron chelator in the vicinity of artemisinin potentiates its action, the linked compds. prepared still retain comparable activities to that of artemisinin.

IT 165068-36-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(mechanism-based development of new antimalarials, synthesis of derivs. of artemisinin attached to iron chelators)

RN 165068-36-0 HCAPLUS

CN 4H-Pyran-4-one, 3-[3-[(decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl)oxy]propoxy]-6-(hydroxymethyl)-, [3R-(3α,5aβ,6β,8aβ,9α,10α,12β,12aR*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



=> d l14 ibib abs hitstr tot

L14 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1995:608133 HCAPLUS

DOCUMENT NUMBER: 123:83751
ORIGINAL REFERENCE NO.: 123:15005a,15008a
TITLE: Mechanism-Based Development of New Antimalarials: Synthesis of Derivatives of Artemisinin Attached to Iron Chelators
AUTHOR(S): Kamchonwongpaisan, Sumalee; Paitayatat, Sumpan; Thebtaranonth, Yodhathai; Wilairat, Prapin; Yuthavong, Yongyuth
CORPORATE SOURCE: Faculty of Science, Mahidol University, Bangkok, 10400, Thailand
SOURCE: Journal of Medicinal Chemistry (1995), 38(13), 2311-16
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB Various derivs. of artemisinin covalently linked to iron chelators, e.g. I, were synthesized, and their antimalarial activities were evaluated. Although results show no indication that the presence of an iron chelator in the vicinity of artemisinin potentiates its action, the linked compds. prepared still retain comparable activities to that of artemisinin.
IT 165068-36-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(mechanism-based development of new antimalarials, synthesis of derivs. of artemisinin attached to iron chelators)
RN 165068-36-0 HCAPLUS
CN 4H-Pyran-4-one, 3-[3-[(decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl)oxy]propoxy]-6-(hydroxymethyl)-, [3R-(3α,5aβ,6β,8aβ,9α,10α,12β,12aR*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



=> d l17 ibib abs hitstr tot

L17 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:312673 HCAPLUS
DOCUMENT NUMBER: 138:321131
TITLE: Preparation of pyranones for treatment of tumors related to GTPases.
INVENTOR(S): Leblanc, Veronique; Leblond, Bertrand; Melle-Milovanovic, Dominique; Lopez Rodriguez, Maria Luz; Viso Beronda, Alma
PATENT ASSIGNEE(S): Exonhit Therapeutics S.A., Fr.
SOURCE: U.S., 24 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6552073	B1	20030422	US 2002-85141	20020301 <--
CA 2477003	A1	20030912	CA 2003-2477003	20030228 <--
WO 2003074508	A1	20030912	WO 2003-IB1050	20030228 <--
WO 2003074508	B1	20031127		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003209924	A1	20030916	AU 2003-209924	20030228 <--
EP 1480966	A1	20041201	EP 2003-743474	20030228
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

JP 2005529079	T	20050929	JP 2003-572976		20030228
US 20050054629	A1	20050310	US 2004-502625		20041022 <--
PRIORITY APPLN. INFO.:			US 2002-85141	A	20020301
			WO 2003-IB1050	W	20030228

OTHER SOURCE(S): MARPAT 138:321131
GI



AB Title compds. [I; R1 = CH2R3, COR3; R2 = H, alkenyl; R3 = OH, OR4, SR4, NR5R6, pyrrolidinyl, piperidinyl; R4 = alkyl, aryl, aralkyl, alkanoyl, arylcarbonyl; R5, R6 = H, alkyl, aryl, aralkyl; n = 1-10; X = O, S, NR7; Y = O; R7 = H, alkyl, aryl, aralkyl], were prepared Thus, 5-[7-(3,4-dichloro-2-propylphenoxy)heptyloxy]-2-hydroxymethyl-4H-pyran-4-one (general preparation outlined) showed IC50 = 5-10 μM against H460 lung carcinoma and HCT116 colon cancer cells, resp.

IT 514170-76-4P 514170-77-5P 514170-78-6P
514170-79-7P 514170-80-0P 514170-81-1P
514170-82-2P 514170-83-3P 514170-84-4P
514170-85-5P 514170-86-6P 514170-87-7P
514170-88-8P 514170-89-9P 514170-90-2P
514170-91-3P 514170-92-4P 514170-93-5P
514170-94-6P 514170-95-7P 514170-96-8P
514170-97-9P 514170-98-0P 514170-99-1P
514171-00-7P 514171-01-8P 514171-02-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of pyranones for treatment of tumors related to
GTPases)

RN 514170-76-4 HCAPLUS
CN 4H-Pyran-4-one, 5-[[5-(4-chlorophenoxy)pentyl]oxy]-2-(hydroxymethyl)- (CA INDEX NAME)



RN 514170-77-5 HCAPLUS
CN 4H-Pyran-4-one, 5-[[5-(3-chlorophenoxy)pentyl]oxy]-2-(hydroxymethyl)- (CA INDEX NAME)



RN 514170-78-6 HCAPLUS
CN 4H-Pyran-4-one, 5-[[5-(3,4-dichlorophenoxy)pentyl]oxy]-2-(hydroxymethyl)- (CA INDEX NAME)



RN 514170-79-7 HCAPLUS
CN 4H-Pyran-4-one, 5-[4-(3,4-dichlorophenoxy)butoxy]-2-(hydroxymethyl)- (CA INDEX NAME)



RN 514170-80-0 HCAPLUS
CN 4H-Pyran-4-one, 5-[[5-(3,4-dichloro-2-propylphenoxy)pentyl]oxy]-2-(hydroxymethyl)- (CA INDEX NAME)



RN 514170-81-1 HCAPLUS
CN 4H-Pyran-4-one, 5-[[5-(4,5-dichloro-2-propylphenoxy)pentyl]oxy]-2-(hydroxymethyl)- (CA INDEX NAME)



RN 514170-82-2 HCAPLUS
CN 4H-Pyran-4-one, 5-[[5-(2-ethoxyphenoxy)pentyl]oxy]-2-(hydroxymethyl)- (CA INDEX NAME)



RN 514170-83-3 HCAPLUS
CN 4H-Pyran-4-one, 5-[[6-(3,4-dichloro-2-propylphenoxy)hexyl]oxy]-2-(hydroxymethyl)- (CA INDEX NAME)



RN 514170-84-4 HCAPLUS
CN 4H-Pyran-4-one, 5-[[7-(3,4-dichloro-2-propylphenoxy)heptyl]oxy]-2-(hydroxymethyl)- (CA INDEX NAME)



RN 514170-85-5 HCAPLUS
CN 4H-Pyran-4-one, 5-[[9-(3,4-dichlorophenoxy)nonyl]oxy]-2-(hydroxymethyl)- (CA INDEX NAME)



RN 514170-86-6 HCAPLUS
CN 4H-Pyran-2-carboxylic acid, 5-[[5-(4-chlorophenoxy)pentyl]oxy]-4-oxo- (CA INDEX NAME)



RN 514170-87-7 HCAPLUS
CN 4H-Pyran-2-carboxylic acid, 5-[[5-(3-chlorophenoxy)pentyl]oxy]-4-oxo- (CA INDEX NAME)



RN 514170-88-8 HCAPLUS
CN 4H-Pyran-2-carboxylic acid, 5-[[5-(3,4-dichlorophenoxy)pentyl]oxy]-4-oxo- (CA INDEX NAME)



RN 514170-89-9 HCAPLUS
CN 4H-Pyran-2-carboxylic acid, 5-[4-(3,4-dichlorophenoxy)butoxy]-4-oxo- (CA INDEX NAME)



RN 514170-90-2 HCAPLUS
CN 4H-Pyran-2-carboxylic acid, 5-[[5-(3,4-dichloro-2-propylphenoxy)pentyl]oxy]-4-oxo- (CA INDEX NAME)



RN 514170-91-3 HCAPLUS
CN 4H-Pyran-2-carboxylic acid, 5-[[5-(2-ethoxyphenoxy)pentyl]oxy]-4-oxo- (CA INDEX NAME)



RN 514170-92-4 HCAPLUS
CN 4H-Pyran-2-carboxamide, 5-[[5-(4-chlorophenoxy)pentyl]oxy]-4-oxo-N-(phenylmethyl)- (CA INDEX NAME)



RN 514170-93-5 HCAPLUS
CN 4H-Pyran-4-one, 3-[[5-(4-chlorophenoxy)pentyl]oxy]-6-(hydroxymethyl)-2-(1E)-1-propen-1-yl- (CA INDEX NAME)

Double bond geometry as shown.



RN 514170-94-6 HCAPLUS
CN 4H-Pyran-4-one, 3-[[5-(3-chlorophenoxy)pentyl]oxy]-6-(hydroxymethyl)-2-(1E)-1-propen-1-yl- (CA INDEX NAME)

Double bond geometry as shown.



RN 514170-95-7 HCAPLUS
CN 4H-Pyran-4-one, 3-[[5-(3,4-dichlorophenoxy)pentyl]oxy]-6-(hydroxymethyl)-2-(1E)-1-propen-1-yl- (CA INDEX NAME)

Double bond geometry as shown.



RN 514170-96-8 HCAPLUS
CN 4H-Pyran-4-one, 3-[[5-(3,4-dichloro-2-propylphenoxy)pentyl]oxy]-6-(hydroxymethyl)-2-(1E)-1-propen-1-yl- (CA INDEX NAME)

Double bond geometry as shown.



RN 514170-97-9 HCAPLUS
CN 4H-Pyran-4-one, 6-(hydroxymethyl)-2-(1E)-1-propen-1-yl-3-[[5-(2-propylphenoxy)pentyl]oxy]- (CA INDEX NAME)

Double bond geometry as shown.



RN 514170-98-0 HCAPLUS
CN 4H-Pyran-2-carboxylic acid, 5-[[5-(4-chlorophenoxy)pentyl]oxy]-4-oxo-6-(1E)-1-propen-1-yl- (CA INDEX NAME)

Double bond geometry as shown.



RN 514170-99-1 HCAPLUS
CN 4H-Pyran-2-carboxylic acid, 5-[[5-(3-chlorophenoxy)pentyl]oxy]-4-oxo-6-(1E)-1-propen-1-yl- (CA INDEX NAME)

Double bond geometry as shown.



RN 514171-00-7 HCAPLUS
CN 4H-Pyran-2-carboxylic acid, 5-[[5-(3,4-dichlorophenoxy)pentyl]oxy]-4-oxo-6-(1E)-1-propen-1-yl- (CA INDEX NAME)

Double bond geometry as shown.



RN 514171-01-8 HCAPLUS
CN 4H-Pyran-2-carboxylic acid, 5-[[5-(3,4-dichloro-2-propylphenoxy)pentyl]oxy]-4-oxo-6-(1E)-1-propen-1-yl- (CA INDEX NAME)

Double bond geometry as shown.



RN 514171-02-9 HCAPLUS
CN 4H-Pyran-2-carboxylic acid, 4-oxo-6-(1E)-1-propen-1-yl-5-[[5-(2-propylphenoxy)pentyl]oxy]- (CA INDEX NAME)

Double bond geometry as shown.



IT 107757-98-2P 107758-01-0P 514171-03-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyranones for treatment of tumors related to GTPases)
RN 107757-98-2 HCAPLUS
CN 4H-Pyran-4-one, 2-(hydroxymethyl)-5-[[5-(2-propylphenoxy)pentyl]oxy]- (CA INDEX NAME)



RN 107758-01-0 HCAPLUS
CN 4H-Pyran-2-carboxylic acid, 4-oxo-5-[[5-(2-propylphenoxy)pentyl]oxy]- (CA INDEX NAME)



RN 514171-03-0 HCAPLUS
CN 4H-Pyran-4-one, 5-[[5-(3,4-dichlorophenoxy)pentyl]oxy]-2-[(phenylmethoxy)methyl]- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1992:151767 HCAPLUS
DOCUMENT NUMBER: 116:151767
ORIGINAL REFERENCE NO.: 116:25692h,25693a
TITLE: Preparation of (pyridinylmethylsulfinyl)benzimidazoles as gastric acid secretion inhibitors
INVENTOR(S): Braendstroem, Arne Elof; Lindberg, Per Lennart; Sunden, Gunnel Elisabeth
PATENT ASSIGNEE(S): Astra AB, Swed.
SOURCE: PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9119712	A1	19911226	WO 1991-SE416	19910611 <--
W: AT, AU, BB, BG, BR, CA, CH, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MC, MG, MW, NL, NO, PL, RO, SD, SE, SU				
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN, GR, IT, LU, ML, MR, NL, SE, SN, TD, TG				
CA 2083606	A1	19911221	CA 1991-2083606	19910611 <--
CA 2083606	C	20010821		
AU 9180617	A	19920107	AU 1991-80617	19910611 <--
AU 649456	B2	19940526		
HU 62882	A2	19930628	HU 1992-4034	19910611 <--
JP 05507714	T	19931104	JP 1991-511436	19910611 <--
JP 3049367	B2	20000605		
EP 593463	A1	19940427	EP 1991-911618	19910611 <--
EP 593463	B1	19990915		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
PL 165898	B1	19950228	PL 1991-297295	19910611 <--
RO 110497	B1	19960130	RO 1992-1543	19910611 <--
AT 184602	T	19991015	AT 1991-911618	19910611 <--
ES 2140391	T3	20000301	ES 1991-911618	19910611 <--
IL 98472	A	19950831	IL 1991-98472	19910612 <--
CN 1058213	A	19920129	CN 1991-105025	19910620 <--
CZ 279434	B6	19950412	CZ 1991-1893	19910620 <--
US 5430042	A	19950704	US 1991-718188	19910620 <--
NO 9204650	A	19921202	NO 1992-4650	19921202 <--
LV 10269	B	19951020	LV 1993-820	19930630 <--
PRIORITY APPLN. INFO.:			SE 1990-2206 A	19900620
			SE 1990-2207 A	19900620
			WO 1991-SE416 A	19910611
OTHER SOURCE(S):	MARPAT 116:151767			

GI





AB Title compds. (I; R1, R2 = H, alkyl, COR5; R3, R4 = Me, Et, cyclopropylmethyl, MeOCH2CH2, Q1; R3R4 = (CH2)n; n = 1-3; R5 = alkyl, alkoxy; one of R1, R2 is always COR5) were prepared Thus,

5-acetyl-6-methyl-2-mercapto-1H-benzimidazole, 3,4-dimethoxy-2-chloromethylpyridine, NaOH, and H2O were refluxed in EtOH to give 62% coupling product, which was oxidized with 3-ClC6H4C(O)OOH/NaHCO3 in CH2Cl2/H2O to give title compound II. II inhibited gastric acid secretion in dogs with ED50 = 0.74 μmol/kg i.v. Tablets were prepared containing II.

IT 139645-13-9P 139645-14-0P 139645-15-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for ulcer inhibitor)

RN 139645-13-9 HCAPLUS
CN 4H-Pyran-4-one, 3-(3-hydroxypropoxy)-2-methyl- (CA INDEX NAME)



RN 139645-14-0 HCAPLUS
CN 4H-Pyran-4-one, 3-(3-methoxypropoxy)-2-methyl- (CA INDEX NAME)



RN 139645-15-1 HCAPLUS
CN 4(1H)-Pyridinone, 3-(3-methoxypropoxy)-2-methyl- (CA INDEX NAME)



L17 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	1987:156276 HCAPLUS
DOCUMENT NUMBER:	106:156276
ORIGINAL REFERENCE NO.:	106:25429a,25432a
TITLE:	Preparation of aralkoxy- and aryloxyalkoxy-substituted kojic acid derivatives as LTD4 inhibitors
INVENTOR(S):	Masateru, Miyano; Shone, Robert L.
PATENT ASSIGNEE(S):	G.D. Searle and Co., USA
SOURCE:	U.S., 11 pp. CODEN: USXXAM
DOCUMENT TYPE:	Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4644071	A	19870217	US 1984-629916	19840711 <--
US 4705871	A	19871110	US 1986-894591	19860808 <--
US 4812584	A	19890314	US 1987-77362	19870724 <--
PRIORITY APPLN. INFO.:			US 1984-629916 A3	19840711
			US 1986-894591 A3	19860808

OTHER SOURCE(S): CASREACT 106:156276; MARPAT 106:156276
GI



AB Title derivs. I [R1 = naphthyl, naphthyloxy, 1,2,3,4-tetrahydronaphth-1- or -2-yl, (un)substituted PhO; R2 = CH2OH, CHO, alkoxycarbonyl, CO2H and its alkali-metal or ammonium salts; m = 1-10] are prepared as LTD4 inhibitors (no data). A mixture of 33.2 mmol (bromopentoxy)acetophenone derivative II (preparation given), 26.6 mmol kojic acid, and 60 mmol anhydrous K2CO3 in DMF was stirred at room temperature for 3 days to give 3.0 g of (phenoxypentoxy)pyranone derivative III, a preferred compound

IT 107757-98-2P 107757-99-3P 107758-00-9P
107758-01-0P 107758-02-1P 107758-03-2P
107758-04-3P 107758-05-4P 107759-81-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as LTD4 inhibitor)

RN 107757-98-2 HCAPLUS

CN 4H-Pyran-4-one, 2-(hydroxymethyl)-5-[[5-(2-propylphenoxy)pentyl]oxy]- (CA INDEX NAME)



RN 107757-99-3 HCAPLUS
CN 4H-Pyran-4-one, 5-[[5-(4-acetyl-3-hydroxy-2-propylphenoxy)pentyl]oxy]-2-(hydroxymethyl)- (CA INDEX NAME)



RN 107758-00-9 HCAPLUS
CN 4H-Pyran-2-carboxaldehyde, 4-oxo-5-[[5-(2-propylphenoxy)pentyl]oxy]- (CA INDEX NAME)



RN 107758-01-0 HCAPLUS
CN 4H-Pyran-2-carboxylic acid, 4-oxo-5-[[5-(2-propylphenoxy)pentyl]oxy]- (CA INDEX NAME)



RN 107758-02-1 HCAPLUS
CN 4H-Pyran-2-carboxylic acid, 4-oxo-5-[[5-(2-propylphenoxy)pentyl]oxy]-, methyl ester (CA INDEX NAME)



RN 107758-03-2 HCAPLUS
CN 4H-Pyran-2-carboxylic acid, 5-[[5-(4-acetyl-3-hydroxy-2-propylphenoxy)pentyl]oxy]-4-oxo- (CA INDEX NAME)



RN 107758-04-3 HCAPLUS
CN 4H-Pyran-2-carboxylic acid, 5-[[5-(4-acetyl-3-hydroxy-2-propylphenoxy)pentyl]oxy]-4-oxo-, methyl ester (CA INDEX NAME)



RN 107758-05-4 HCAPLUS
CN 4H-Pyran-2-carboxylic acid, 5-[3-(2-naphthalenyloxy)propoxy]-4-oxo-, methyl ester (CA INDEX NAME)



RN 107759-81-9 HCAPLUS
CN 4H-Pyran-2-carboxylic acid, 5-[3-(2-naphthalenyloxy)propoxy]-4-oxo-, sodium salt (9CI) (CA INDEX NAME)



● Na

L17 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1986:515074 HCAPLUS
DOCUMENT NUMBER: 105:115074
ORIGINAL REFERENCE NO.: 105:18634h,18635a
TITLE: Heterocyclic compounds and their use
INVENTOR(S): Kiyoshi, Murase; Toshiyasu, Mase; Hiromu, Hara; Kenichi, Tomioka
PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 94 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
EP 181779	A1	19860521	EP 1985-308227	19851112	<--
EP 181779	B1	19940316			
R: AT, BE, CH, DE, FR, GB, IT, LI, NL, SE					
ZA 8508493	A	19860730	ZA 1985-8493	19851105	<--
ES 548772	A1	19870901	ES 1985-548772	19851111	<--
SU 1470186	A3	19890330	SU 1985-3979033	19851111	<--
JP 62174057	A	19870730	JP 1985-253562	19851112	<--
JP 63035626	B	19880715			
CA 1269982	A1	19900605	CA 1985-495080	19851112	<--
AT 102930	T	19940415	AT 1985-308227	19851112	<--
ES 556746	A1	19871216	ES 1986-556746	19860625	<--
ES 556747	A1	19871216	ES 1986-556747	19860625	<--
ES 556748	A1	19871216	ES 1986-556748	19860625	<--
ES 556749	A1	19871216	ES 1986-556749	19860625	<--
ES 556750	A1	19871216	ES 1986-556750	19860625	<--
ES 556751	A1	19871216	ES 1986-556751	19860625	<--
ES 556752	A1	19871216	ES 1986-556752	19860625	<--
ES 556753	A1	19871216	ES 1986-556753	19860625	<--
SU 1438610	A3	19881115	SU 1986-4028334	19861021	<--
SU 1491337	A3	19890630	SU 1986-4028351	19861024	<--
SU 1498389	A3	19890730	SU 1986-4028367	19861024	<--
SU 1452481	A3	19890115	SU 1986-4028381	19861027	<--
SU 1493105	A3	19890707	SU 1986-4028350	19861027	<--
SU 1454249	A3	19890123	SU 1986-4028405	19861029	<--
US 4855310	A	19890808	US 1988-173734	19880325	<--
US 4908368	A	19900313	US 1989-362959	19890607	<--

US 5177215	A	19930105	US 1990-486550		19900228 <--
US 5258395	A	19931102	US 1992-960125		19921013 <--
PRIORITY APPLN. INFO.:			JP 1984-238991	A	19841112
			JP 1985-219327	A	19851001
			US 1985-796628	A2	19850811
			EP 1985-308227	A	19851112
			US 1988-173734	A3	19880325
			US 1989-362959	A3	19890607
			US 1990-486550	A3	19900228

OTHER SOURCE(S): CASREACT 105:115074; MARPAT 105:115074

GI



I



II

AB Heterocyclic compds. [I; R1 = C1-6 acyl; R2 = C1-6 alkyl; X = C1-6 alkylene or hydroxyalkylene; Y = O, S, carbonylimino, iminocarbonyl; Z = (un)substituted 5- of 6-membered heterocyclic ring containing O, S, N which may be fused with a benzene ring], useful for the treatment and prevention of allergic diseases, are prepared Thus, thiadiazole II was prepared by reacting 4-(3-bromopropoxy)-2-hydroxy-3-propylacetophenone and [(5-mercapto-1,3,4-thiadiazol-2-yl)thio]acetic acid. II antagonized the actions of SRS-A in guinea pig ileum and trachea and inhibited SRS-A-mediated anaphylactic asthma in conscious guinea pigs. A tablet was formulated containing II 30, lactose 104, starch 57, hydroxypropyl cellulose 4, Ca CM-cellulose 4, and Mg stearate 1 mg.

IT 104073-60-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as antiallergic)

RN 104073-60-1 HCAPLUS

CN 4H-Pyran-4-one, 5-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]-2-(hydroxymethyl)- (CA INDEX NAME)



L17 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1986:461480 HCAPLUS
DOCUMENT NUMBER: 105:61480
ORIGINAL REFERENCE NO.: 105:10055a,10058a
TITLE: Unsaturated cyclic amido-substituted ether compounds
INVENTOR(S): Itoh, Hiroshi; Tanaka, Tomio; Nitta, Atsuhiko; Kamio, Hideo
PATENT ASSIGNEE(S): Mitsui Toatsu Chemicals, Inc. , Japan
SOURCE: Eur. Pat. Appl., 78 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 155177	A2	19850918	EP 1985-301695	19850312 <--
EP 155177	A3	19870204		
EP 155177	B1	19901031		
R: CH, DE, FR, GB, IT, LI, NL, SE				
JP 60193955	A	19851002	JP 1984-46532	19840313 <--
JP 05073739	B	19931015		
US 4649219	A	19870310	US 1985-708568	19850306 <--
CA 1244012	A1	19881101	CA 1985-475877	19850306 <--

PRIORITY APPLN. INFO.: JP 1984-46532 A 19840313
OTHER SOURCE(S): CASREACT 105:61480; MARPAT 105:61480
GI



I

AB Unsatd. cyclic amido-substituted ether compds. I (Z1, Z3 = cyclic group; Z4 = C1-5 alkylene, C2-5 alkenylene, oxyalkylene group, or aminoalkylene group; R3, R4 = halogen, OH, oxo, CN, NO2, SH, S, or a salt thereof, C1-20 alkyl, C2-15 alkenyl, C1-20 haloalkyl, amine group or substituted amine, H, lower alkyl, a carbonyl group, an acid group or salt thereof, or amidopolymethylene group; Z2 = 0, carbonyl, thio, sulfonyl, azo, C1-5 alkylene, C2-5 alkenylene; R2 = H or Me; a = 0-5; m = 4-20; n, p = 0-4 and cannot = 0 at the same time, b = 0 or 1) are useful as crosslinking agents or reactive diluents for hygroscopic polymers. Thus, 1.96 g acrylic amide and 4.0 g 2,2-bis(4-bromobutoxyphenyl)propane were dissolved in 20 mL DMF and heated at 0-5° for 6 h in the presence of KOH and phenothiazine to give 3.01 g 2,2-bis[4-(4-acrylamidobutoxy)phenyl]propane II. N-Acryloylpyrrolidine containing 0.2% II was mixed with 1% tert-butylperoxy-2-ethylhexanoate and polymerized at 40° for 50 h to give a hygroscopic flexible block polymer.

IT 102414-01-7P
RL: PREP (Preparation)
(preparation of, as crosslinking agent for unsatd. polymers)
RN 102414-01-7 HCAPLUS
CN 2-Propenamide, N-[4-[(2-methyl-4-oxo-4H-pyran-3-yl)oxy]butyl]- (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	76.16	657.99
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-9.60	-13.60

STN INTERNATIONAL LOGOFF AT 10:50:17 ON 04 AUG 2008